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Abstract 
Stroke is a leading cause of permanent disability worldwide. Physiotherapy 
facilitates motor recovery after stroke but recovery is often incomplete, highlighting the 
need to develop other methods (e.g. utilizing more intensive rehabilitation or combining 
rehabilitation with drug therapy) to augment existing therapies. 
Depression is a common occurrence after stroke and consequently a large 
population of stroke patients are treated with antidepressants. Most antidepressants act to 
facilitate actions of serotonin, norepinephrine, or both. Despite the prevalence of 
antidepressant use, little is known about how these drugs might affect the recovery of 
motor function in these patients. The involvement of serotonin and norepinephrine in 
motor recovery after focal ischemia in the rat was the focus of this thesis. 
Serotonin selective reuptake inhibitors are often the antidepressants of choice in 
the stroke population. In the first experiment a chronic dose of fluoxetine (a serotonin 
specific reuptake inhibitor) was combined with rehabilitation to determine if it facilitated 
motor recovery. No effect of the drug was found suggesting that facilitating the serotonin 
system has little or no effect on motor recovery. 
In the second experiment norepinephrine was depleted using N-(2-chloroethyl)-N-
ethyl-2-bromobenzylamine, a neurotoxin specific for terminals of norepinephrine cells of 
the locus coeruleus. Depleting norepinephrine terminals improved recovery in animals 
exposed to enriched rehabilitation as well as standard housed animals. This suggests that 
norepinephrine plays a role in recovery of function but that role may be more 
complicated than previously thought. 
11 
The final experiment compared four different endothelin-1 models of focal 
ischemia, including the models used in the previous experiments (experiment 1: focal 
ischemia of the cortex and striatum by localized injection or experiment 2: by injection 
adjacent to the middle cerebral artery). While all four models produced similar 
behavioural deficits the model that targeted the middle cerebral artery (the most 
commonly used model) yielded the lowest success rate (as determined by survival and 
ability to produce a forelimb reaching deficit). The more successful model combining 
cortical and striatal injections of endothelin-1 was further characterized using magnetic 
resonance imaging and found to have blood flow dynamics similar to clinical stroke. 
The results of this thesis help to clarify previous findings regarding the anti-
depressant, fluoxetine and recovery of function. In addition, the current findings further 
explore the role of norepinephrine in stroke recovery with indications for future research. 
Finally, I introduce a new endothelin-1 model of focal ischemia that is a more consistent 
and clinically relevant alternative to existing models. 
lll 
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Chapter 1: Introduction 
1.1 General rationale 
With a mortality rate of approximately 30% stroke is the third leading cause of 
death worldwide (Dimagl et al., 1999; Lo et al., 2003). In Canada alone there are 40,000 
to 50,000 new stroke victims per year. Of those that survive, approximately 70-80% will 
have an upper-extremity impairment (Parker et al., 1986; Nakayama et al., 1994) that 
greatly affects independence and quality of life, and approximately 30 % will remain 
severely disabled such that they will be dependant on others for certain activities of daily 
living, making stroke a leading cause of long-term disability (Muntner et al., 2002; 
Carmichael, 2005). Given the aging population structure of Canada and the fact that the 
risk of stroke doubles every 10 years after the age of 55, there is a trend towards 
increasing stroke incidence (Feigin et al., 2003) and an increasing need for not only 
preventative and neuroprotective strategies but also therapies aimed at improving 
function after a stroke. 
1.2 Pathology of stroke 
Strokes fall into two categories; 1. Hemorrhagic, resulting from a rupture of a 
blood vessel leaking blood into the brain, and 2. Ischemic, which results from 
interruption of blood flow to the brain due to an embolus, thrombus or cardiac arrest. 
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Approximately 80 % of strokes are ischemic in nature and this type of stroke is the focus 
of this thesis. 
Blood supplies oxygen and glucose to cells, which are critical to cell survival. A 
reduction of blood flow results in energy depletion, which can have a number of 
devastating effects on a neuron. Without energy neurons are unable to maintain ion 
gradients, which causes membrane depolarization and release of neurotransmitters, 
including the excitatory neurotransmitter glutamate, which in turn causes depolarization 
of neighbouring cells setting up a cycle or wave of depolarizations that spread outward 
from the most densely ischemic region, the ischemic core (Rossmann, 1994; De Keyser 
et al., 1999; Dimagl et al., 1999; Barber et al., 2003). Activation of glutamate receptors 
results in an influx ofNa + and Ca2+ that further depolarizes the cell as well as initiating 
other cascades (Rossmann, 1994; De Keyser et al., 1999; Dimagl et al., 1999; Barber et 
al., 2003). Protein synthesis is impaired, acidosis occurs causing failure ofNa+-K+ 
pumps and Ca2+ buffering systems resulting in an even larger elevation of intracellular 
Ca2+ (Rossmann, 1994; De Keyser et al., 1999; Dimagl et al., 1999; Barber et al., 2003). 
The end result is the activation of different genes involved in cell death pathways, nitric 
oxide and free radical formation, inflammation and cytokine release (Rossmann, 1994; 
De Keyser et al., 1999; Dimagl et al., 1999; Barber et al., 2003). Following ischemia, 
cells in the ischemic core die rapidly as a result of necrosis whereas in the border zone of 
the infarct, the ischemic penumbra, cells die more slowly as a result of gene induction 
leading to apoptosis (Back et al., 2004; Carmichael, 2005). Many of these mechanisms 
were established in in vitro and in vivo models of stroke but are relevant to the 
2 
mechanisms of human stroke (Dimagl et al., 1999). For the majority ofhuman patients 
the final infarct size is typically established 24 to 36 h after onset but infarcts may evolve 
over a week (Pantano et al., 1999) with final size depending on the degree and the 
duration of blood flow reduction (Back et al., 2004). Since some cell death is gradual 
this suggests that there is a therapeutic time window when treatment could prevent 
further damage. 
1.3 Neuroprotection studies 
Until recently most stroke research has been focused on cellular events underlying 
ischemic injury with the goal of developing neuroprotective drug therapies. While cells 
exposed to near total ischemia die within minutes and cannot be saved (ischemic core), 
cells in regions with partial ischemia due to collateral blood flow may take hours or days 
to die (ischemic penumbra) and thus may be salvaged. Several different drugs have been 
explored as potential neuroprotective agents targeting glutamate receptors, Ca2+ channels 
and free radicals, but to date none has been successful in clinical trials (Lo et al., 2003). 
Several of these drugs should not have been tested in phase III clinical trials based on the 
available animal studies, since these studies had several methodological problems 
including inadequate control of temperature, unrealistic treatment times, inadequate 
survival time and lack of behavioural endpoints (for review see Corbett and Nurse, 1998; 
De Keyser et al., 1999; Jonas et al., 2001). In hindsight it is not surprising that the 
clinical trials failed. The clinical failure of these drugs was primarily due to lack of effect 
or to severe side effects (De Keyser et al., 1999). One difficulty in treating stroke by 
3 
targeting specific receptors or a single step of an intracellular cascade is the heterogeneity 
of stroke (De Keyser et al., 1999). Different types of neurons and different regions of the 
brain will respond differently to loss of blood flow and it is likely that a more broad range 
of therapeutic agents would be required rather than a single agent. 
1.4 Current treatment for acute stroke 
1. 4.1 Hypothermia 
Approximately 50 % of human ischemic stroke patients develop a fever after the 
insult and those that do have worsened outcome (for review see Corbett and Thornhill, 
2000). Decreasing body temperature even by a few degrees can have a neuroprotective 
effect after ischemia. Some of the drugs tested as potential neuroprotective agents 
actually cause hypothermia and when temperature is controlled the beneficial effects of 
the drug are lost (Nurse and Corbett, 1996). Several animal studies have shown that 
decreasing brain' temperature reduces cell death, improves electrophysiological properties 
of cells at risk and improves functional outcome after global and focal ischemia 
(Colbourne and Corbett, 1994, 1995; Corbett et al., 1997; Colbourne et al., 2000; Dong et 
al., 2001). Clinical studies have shown that the use of hypothermia after stroke, traumatic 
brain injury, or cardiac arrest decreases mortality and improves neurological outcome 
(Schwab et al., 1998; Kammersgaard et al., 2000; Curfman, 2002; Safar and Kochanek, 
2002; Kochanek and Safar, 2003; Mcintyre et al., 2003). While neuroprotective drugs 
4 
targeted a single step in a cascade of cellular events, hypothermia is thought to be 
successful because it modulates multiple processes involved in cell death. Protective 
mechanisms may include decreased metabolic rate, increased serum Mg2+ which would 
block glutamate receptors, alteration of Ca2+ signaling, restoration of normal protein 
synthesis, decreased free radicals, interruption of apoptosis, and attenuation of 
inflammation (Colbourne et al., 1997; Corbett and Thornhill, 2000). 
Despite the plethora of animal and human studies supporting hypothermia as 
beneficial after stroke it is not commonly used in acute stroke treatment. This is likely 
due to several factors, including the risk of side effects such as pneumonia as well as a 
lack of emergency room guidelines outlining the extent and duration of a cooling 
treatment. The animal and clinical studies listed above used various degrees and 
durations of cooling with differential results. Despite the different methods there does 
seem to be a consensus that mild hypothermia (~33 °C) for a prolonged period (several 
hours) seems optimal, but the parameters in humans have yet to be delineated. 
1.4.2 Tissue plasminogen activator 
Tissue plasminogen activator (t-PA) is a protease that can break up clots and is 
effective in restoring blood flow if given within 3 hours of stroke onset (Albers et al., 
2002). Despite the potential benefits oft-PA it is estimated that only 20-25% of ischemic 
stroke patients get to the hospital within the 3 hour time window (Barber et al., 2001). 
Due to the small time window and the increased risk of hemorrhage with t-PA only about 
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5% of ischemic stroke patients are actually treated with the drug (Barber et al., 2001). 
Ischemic stroke evolves over time and even if given t-P A the lesion will continue to 
increase in size over 7 days in about 113 of the stroke population resulting in a lower 
degree of clinical recovery (Pantano et al., 1999). Therefore, only a small population of 
stroke victims will receive this drug and not all of such individuals will have a complete 
recovery. 
1.5 Rehabilitation 
For the majority of stroke patients, including many of those treated with 
hypothermia or t-PA, there will be lasting functional impairments. For these patients 
physiotherapy, speech therapy and occupational therapy are the only treatment options 
available. 
1.5.1 Physiotherapy and brain plasticity 
Rehabilitation has been described as an active form of learning. It is now known 
that the brain is extremely plastic and that neural circuits are modified by cognitive or 
motor learning (for review see Nudo et al., 2001; Kolb, 2003). There is strong evidence 
to suggest that rehabilitation (physiotherapy) is beneficial in many stroke patients, 
reducing mortality and morbidity (Langhorne and Duncan, 2001; Van Peppen et al., 
2004). 
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Human studies have shown that stroke to the motor cortex resulting in a paretic 
hand alters the areas of cortex that are activated during movement of the hand (Stephan 
and Frackowiak, 1997; Marshall et al., 2000; Feydy et al., 2002). Subsequent activation 
often shifts to surrounding motor areas or to motor areas of the contralateral cortex. As 
patients regain function of the hand the activation maps change again, reflecting the role 
that cortical plasticity plays in recovery of function (Stephan and Frackowiak, 1997; 
Marshall et al., 2000; Carey et al., 2002; Feydy et al., 2002; Cramer, 2004). 
1.5.2 Animal studies and brain plasticity 
Animal studies have shown that extensive cortical rewiring takes place after brain 
injury. Areas surrounding the lesion form new connections with other cortical regions as 
shown by tract tracing studies (Carmichael et al., 2001; Dancause et al., 2005). Changes 
in dendritic branching and spine density, axonal sprouting, and altered protein levels have 
also been observed after various types of brain injury (Uryu et al., 2001; Gonzalez and 
Kolb, 2003; Griesbach et al., 2004). Similar to humans, reorganization of cortical maps 
occurs in animals after ischemia (Nudo and Milliken, 1996), and cortical plasticity is 
experience dependent (Nudo et al., 1996a; Nudo et al., 1996b). Specifically, a subtotal 
lesion to the hand representation of the cortex can result in loss of digit representation in 
the adjacent undamaged cortex but rehabilitative training can prevent this loss and in 
some animals even expand digit representation into adjacent areas that were formerly 
responsible for elbow or shoulder function or motor areas of the contralateral cortex 
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(Nudo and Milliken, 1996; Nudo et al., 1996b). Some shifts in cortical activation occur 
immediately after injury, suggesting that connections already exist between these areas 
and perhaps are unmasked or disinhibited as a result of injury. In other instances changes 
occur slowly over the rehabilitation process suggesting that cortical rewiring is occurring 
(Lee and van Donkelaar, 1995; Cramer and Chopp, 2000). 
1. 5. 3 Enhancing functional recovery by environmental manipulation 
As mentioned previously, the brain exhibits plasticity and is responsive to 
changes in behaviour and external stimuli. Simply placing an animal in an enriched 
environment that encourages exploration, exercise, and socialization results in 
morphological changes in the brain (Will and Kelche, 1992). This is accomplished by 
housing rats socially ( 4-8 rats per cage) in large cages with multiple shelves, and an 
assortment of objects that are frequently changed. Enriched environments in normal 
animals increase dendritic branching and spine numbers, neuron size, and induce 
neurogenesis, synaptogenesis, and up regulate several growth factors associated with 
plasticity such as neurotrophin-3, nerve growth factor (NGF) (and its receptors), and 
brain derived neurotrophic factor (BDNF) in the hippocampus, basal forebrain and the 
cortex (Torasdotter et al., 1998; Pham et al., 1999; Ickes et al., 2000; Mohammed et al., 
2002; Briones et al., 2004). 
Environmental enrichment has also been shown to be beneficial after brain injury. 
A combination of enriched environment and forelimb reaching after a transient middle 
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cerebral artery occlusion (MCAo) improves forelimb function and motor coordination in 
rats (Biemaskie and Corbett, 2001). The same study also showed that enriched 
rehabilitation treatment increased the amount of dendritic branching in the contralateral 
hemisphere compared to regularly housed animals (Biemaskie and Corbett, 2001 ). After 
permanent MCAo, enriched environment increases NGF-induced genes A and B, which 
correlate with functional recovery on a rotating pole task (Dahlqvist et al., 2003), and 
also increases spine density in the contralateral cortex (Johansson and Belichenko, 2002). 
After transient global ischemia, an enriched environment improves performance in odor 
discrimination, object exploration tasks and spatial memory, and increases BDNF in the 
hippocampus (Gobbo and O'Mara, 2004), and enriched environment has also been shown 
to increase synaptogenesis in the hippocampus after global ischemia (Briones et al., 
2004). 
Many of the plasticity effects of environmental enrichment are the same as those 
seen after ischemia. Not only does the amount of dendritic branching correlate with the 
amount of injury but also the amount of recovery seen after environmental enrichment 
(Biemaskie et al., 2004). A number of the plasticity-associated changes that occur after 
ischemia occur in the first few weeks (Stroemer et al., 1995; Kawamata et al., 1996; 
Dahlqvist et al., 1999) and environmental enrichment provides optimal benefit when 
initiated within the first 2 weeks after ischemia (Biemaskie et al., 2004). Indeed, if the 
initiation of enrichment/rehabilitation is delayed to 30 days (common clinically) there is 
little functional recovery and no increase in dendritic branching in the cortex (Biemaskie 
et al., 2004). 
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Environmental enrichment studies are good examples of how animal studies can 
directly impact clinical practices. Indeed, these animal studies relating to stroke 
rehabilitation have generated clinical studies examining such things as patient time 
engaged in therapy, socialization and activity (Teasell et al., 2005a). The results of 
clinical and animal studies related to environmental enrichment are increasingly being 
used as evidence to support change to current physiotherapy practices for stroke patients 
(Teasell et al., 2005a; Teasell et al., 2005b ). 
1.5.3 Enhancing recovery through drug therapy: amphetamine 
Just as physiotherapy in humans or environmental enrichment in animals 
improves recovery of function, so too can certain drugs. Amphetamine, which increases 
release of monoamines, is one of the most widely studied drugs shown to promote 
recovery of function after brain injury (for review see Gladstone and Black, 2000). In 
animal studies it has been shown to increase performance on a beam walking task after 
cortical injury in cats as well as rats (Feeney et al., 1982; Hovda and Fenney, 1984; 
Goldstein and Davis, 1990c ), and speeds recovery at a maze task (Hurwitz et al., 1991 ). 
A more recent study showed that amphetamine after MCAo improved performance on a 
grid walking task and water maze, and that the drug increased growth associated protein 
(GAP)-43 and synaptophysin (markers for neural sprouting and synaptogenesis) 
(Stroemer et al., 1998). It is important to note that amphetamine needs to be paired with 
a training task in order for benefit to be seen. If animals are restrained to prevent 
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movement after given amphetamine there is no improvement seen on the beam task 
(Feeney et al., 1982). 
The effect of amphetamine in stroke patients is less clear. Early pilot studies 
suggested that single or multiple doses of amphetamine paired with traditional 
physiotherapy improves motor performance in individual sessions and also over the long 
term (Crisostomo et al., 1988; Walker-Batson et al., 1995). However, these studies only 
had 8 and 1 0 patients respectively while two recent studies with more patients (71 and 
31) have shown no benefit of amphetamine (Platz et al., 2005; Gladstone et al., 2006). 
Differences in outcome may be partly due to stroke severity, age of the patients and delay 
from stroke to treatment time. Perhaps because of the contradictory data, amphetamine is 
not widely used in stroke patients. Amphetamine is a stimulant, and while some studies 
report that there are few side effects (Crisostomo et al., 1988; Walker-Batson et al., 
1995), there are concerns about giving the drug to an aged population and a population 
with a high percentage of cardiac complications. 
The mechanism by which amphetamine improves recovery is thought to be its 
ability to increase the release of monoamines. Amphetamine increases dopamine (DA), 
serotonin (5-HT) and norepinephrine (NE) (Gladstone and Black, 2000) levels in the 
brain and it has been suggested that other drugs that target these neurotransmitters may 
also be beneficial. 5-HT and NE action is also increased by antidepressant drugs, which 
have also been explored in stroke patients due to an increased tendency of stroke patients 
to develop depression. 
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1.6 Post stroke depression (PSD) 
While the prevalence of depression in the average adult population is 
approximately 5 %, the prevalence in stroke patients is anywhere from 18 to 79% 
(Gordon and Hibbard, 1997; Singh et al., 2000; Gillen et al., 2001). The wide range of 
prevalence is likely due to the difficulty in diagnosing PSD. In the average population, 
indicators of depression such as fatigue or inability to concentrate are not as reliable in 
stroke patients for obvious reasons (Gordon and Hibbard, 1997). Nonetheless, most 
studies conclude that a high percentage of stroke patients suffer PSD and that it greatly 
affects the patient's recovery. PSD is associated with decreased quality of life (QOL) 
(Kauhanen et al., 2000), increased disability (Paolucci et al., 2001), and increased 
mortality (Jorge et al., 2003; Robinson, 2003). 
QOL assessment is done by surveying and evaluating patients on several different 
scales to rate quality of physical, psychological, functional, social, and general health. 
One study found that minor and major depression significantly decreased QOL scores in 
all areas measured and that depression is one of the most important determinants of low 
QOL scores after stroke (Kauhanen et al., 2000). The above study found that depression 
resulted in significantly lower physical functioning scores (Kauhanen et al., 2000), a 
finding reported elsewhere (Gillen et al., 2001; Paolucci et al., 2001; Robinson, 2003). 
Patients with PSD respond similarly to rehabilitation, but even if treated with 
antidepressants they have greater disabilities in coping with activities of daily living, and 
lower independence and mobility scores on admission and discharge (Paolucci et al., 
2001). One of the more surprising effects ofPSD is an increase in mortality. A 10 year 
12 
follow up of stroke patients revealed that the mortality rate increased from 41% in non-
depressed patients to 70% of those that suffered PSD (Robinson, 2003). 
When PSD is suspected, antidepressants are often prescribed and several different 
types have shown to be effective in improving not only mood but also motor function. 
Table 1.1 summarizes some of the antidepressants that have been tested after PSD and 
the outcomes used. Classes of antidepressants include: 1) Tricyclics, drugs that increase 
NE and 5-HT by blocking the amine transporter pump for NE, 5-HT, or both 
neurotransmitters, 2) 5-HT selective reuptake inhibitors (SSRI) that increase brain levels 
of 5-HT by blocking the pump responsible for reuptake of 5-HT, and 3) Monoamine 
oxidase inhibitors (MAOI) that prevent the oxidation of both NE and 5-HT. There are 
also NE specific reuptake inhibitors but they have received little testing as yet for PSD. 
All classes of drugs are associated with side effects, which may limit their use in the 
stroke population, and depending on the study, different drugs are listed as appropriate 
for PSD. Despite the high prevalence ofPSD there are surprisingly few studies that have 
looked at the effects of antidepressants on recovery after stroke and many of the studies 
listed in Table 1 had fewer than 100 subjects, highlighting a need for further 
investigation. 
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1. 7 Antidepressants and neuroplasticity: rationale for chapter 2 
1. 7.1 Combined action antidepressants 
A number of antidepressants exert their effect by increasing the action of both NE 
and 5-HT. Nortriptyline is one such drug that has shown to be effective in treating PSD 
and promoting motor recovery after stroke (Lipsey et al., 1984; Gonzalez-Torrecillas et 
al., 1995; Robinson et al., 2000). 
In animals there have been several studies suggesting that antidepressants 
targeting both NE and 5-HT may contribute to neural plasticity. For example, 
imipramine has been shown to increase cAMP response element binding protein (CREB) 
mRNA (Nibuya et al., 1996), and tranylcypromine (MAOI) restores BDNF levels to 
normal in rats subjected to stress (Russo-Neustadt et al., 2001). These drugs also 
increase hippocampal neurogenesis (Malberg et al., 2000). Both CREB and BDNF play a 
role in synaptic plasticity as well as neurogenesis (Duman et al., 2000; Finkbeiner, 2000) 
and infusion of BDNF into the dentate gyrus of the hippocampus produces antidepressant 
effects in behavioural models of depression (Shirayama et al., 2002). Figure 1.1 shows a 
schematic diagram of how antidepressants might mediate trophic effects through CREB 
andBDNF. 
14 
1. 7. 2 Serotonergic antidepressants 
Although the exact mechanisms of depression are poorly understood, it is known 
that drugs that increase the action of 5-HT are effective in treating depression in many 
people including those suffering PSD (see Table 1.1). 5-HT is involved in wakefulness 
and attention as well as facilitation of motor output (Jacobs and Fornal, 1999), and it has 
been suggested that in addition to the ability to improve mood, antidepressants that 
increase 5-HT also improve motor function. 
Using fMRI, a single dose ofparoxetine (a SSRI) was shown to hyperactivate the 
motor cortex when healthy subjects were performing a hand task (Loubinoux et al., 
2002b). This drug also increased motor performance through practice of tests of 
coordination and dexterity (Loubinoux et al., 2002a). Similar modulation of cortical 
activation has also been seen after a single dose offluoxetine (a SSRI) in healthy subjects 
(Loubinoux et al., 1999). Hyperactivation of the motor cortex was also observed after a 
single dose of fluoxetine in stroke patients, which correlated with improved grip strength 
and finger tapping (Pariente et al., 2001 ). Fluoxetine has been shown to dilate small 
cerebral arteries and increase cerebral blood flow in rats, which may underlie the 
increased cortical activation and motor facilitation (Ungvari et al., 1999). 
Conversely, chronic doses ofparoxetine in healthy subjects resulted in a 
hypoactivation of the motor cortex when performing a hand task, but this decreased 
activation correlated with improved motor performance in a finger tapping task 
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suggesting that paroxetine increased the efficiency of cerebral motor processing 
(Loubinoux et al., 2005). 
While increasing 5-HT results in immediate changes in cortical activation, the 
mechanisms that promote motor recovery after brain injury may involve other mediators 
of neural plasticity. Chronic treatment with fluoxetine and sertraline (another SSRI) 
increases levels of cAMP response element binding protein (CREB) mRNA in the 
hippocampus (Nibuya et al., 1996). In addition, fluoxetine increases mRNA for BDNF 
and its receptor, tyrosine receptor kinase (trk)B in the hippocampus (Nibuya et al., 1996; 
Coppell et al., 2003). Fluoxetine has also been shown to increase hippocampal 
neurogenesis in normal rats (Malberg et al., 2000) and prevent decreased neurogenesis of 
the hippocampus in response to inescapable shock (an animal model of depression) 
(Malberg and Duman, 2003). 
Despite the promising results of imaging studies and studies demonstrating that 
SSRis can modulate neural plasticity, there are few studies that have explored their 
potential to improve motor recovery after ischemia. One study that examined fluoxetine 
given for 10 days after a MCAo in rats found that fluoxetine failed to improve recovery 
on a motor task or a spatial memory task (Jolkkonen et al., 2000a). While the results of 
this study are discouraging it is important to note that only one test of motor function was 
used and it was a test on which there is considerable spontaneous recovery after stroke. 
Clinically it is not useful to test drugs on deficits that are so transient since it is unlikely 
that a drug would be given to a patient for an impairment that would resolve in 2 weeks. 
Because of this we felt that further investigation of fluoxetine was warranted using more 
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sensitive behavioural tests and longer treatment times that would better approximate the 
clinical post-stroke scenerio. The main goal of the second chapter of this thesis was to 
test the hypothesis that fluoxetine would improve motor recovery after focal ischemia in 
rats. 
Citalopram and paroxetine both increase extracellular 5-HT levels in the rat 
diencephalon more than fluoxetine and have a higher affinity for the 5-HT transporter 
(Felton et al., 2003), but despite this, fluoxetine was chosen over other SSRis for study in 
chapter 2 because of the previous studies showing some promise after PSD (Table 1.1) 
and the wealth of data linking fluoxetine to neural plasticity. 
1. 7.3 Noradrenergic antidepressants 
The other neurotransmitter targeted by antidepressants is NE. Maprotiline is 
relatively selective for NE and has been shown to improve symptoms of PSD but does 
not improve motor function (Dam et al., 1996). Reboxetine, a selective NE reuptake 
inhibitor has also been found to be effective in treating PSD but has not been explored as 
a facilitator of motor recovery (Rampello et al., 2005). In animals, reboxetine has been 
shown to increase neurogenesis in the hippocampus (Malberg et al., 2000) and 
desipramine (also a selective NE reuptake inhibitor) has been shown to increase CREB 
mRNA (Nibuya et al., 1996). Despiramine has also been show to facilitate motor 
recovery after a sensorimotor cortex lesion (Boyeson and Harmon, 1993) but failed to 
show any benefit after MCAo (Jolkkonen et al., 2000b). Despite the lack of studies using 
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noradrenergic antidepressants there is additional evidence supporting the idea that 
increasing NE release with other drugs (i.e. a2-adrenergic antagonists) enhances neural 
plasticity and motor recovery after brain injury (Sutton and Feeney, 1992). 
1.8 Noradrenergic theory: rationale for chapter 3 
Noradrenergic pharmacotherapy is a phrase used to describe the experimental up 
regulation ofNE with various drugs to facilitate recovery of function after brain injury. 
Much of the support for this theory began when amphetamine was shown to facilitate 
motor recovery after cortical injury in cats, rats, and in some human studies (see section 
1.5.3). This effect can be mimicked by intraventricular infusion ofNE (Boyeson and 
Feeney, 1990) as well as by treating animals with a 2-adrenergic receptor antagonists that 
act on pre synaptic and somatic receptors to increase release ofNE (Sutton and Feeney, 
1992). Atipamezole, an a2-adrenergic antagonist, speeds recovery in limb-placing and 
beam walking tasks after a transient MCAo (Jolkkonen et al., 2000b; Butovas et al., 
2001; Puurunen et al., 2001) but seems to have no effect on spatial learning and memory 
tasks after focal or global ischemia (Puurunen et al., 1997; Puurunen et al., 2001), 
suggesting that the effects may be specific to motor tasks. 
Not only does increasing NE seem to improve recovery but decreasing NE may 
also impair recovery. After cortical injury there is a reduction in monoamines, including 
NE that remains reduced for 40 days, as well as a reduction in at-adrenergic receptors 
(Robinson et al., 1975; Dunn-Meynell et al., 1994; Prasad et al., 1994). Prazosin, an a 1-
adrenergic antagonist (blocks post-synaptic effects ofNE) blocks motor training-
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mediated plasticity in cortical activation in healthy humans (Sawaki et al., 2003) and 
reinstates motor impairment on the beam walking task in rats (Sutton and Feeney, 1992). 
Similarily, clonidine, an a 2-adrenergic agonist slows the rate of beam walking recovery 
after a cortical injury in rats (Goldstein and Davis, 1990b ). 
While these studies do suggest a role for NE in recovery it is important to note 
that amphetamine increases 5-HT and DA in addition toNE. In addition, a 2-adrenergic 
antagonists also increase DA and prazosin and clonidine decrease levels of 5-HT and DA 
in addition toNE (Gobert et al., 1998; Gladstone and Black, 2000; Iwasaki et al., 2006). 
A more direct approach to determining ifNE is required for motor recovery after 
ischemia would be to selectively deplete NE projections from the locus coeruleus (LC) 
with N-(2-chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4), a neurotoxin that leaves 
5-HT and DA levels intact. Chapter 3 examines the postulated role ofNE in motor 
recovery. 
1.9 Non-ischemic models of injury 
Since the goal of this thesis is to contribute to the knowledge of recovery of 
function after stroke it is evident that a clinically relevant animal model of stroke should 
be used. However, several studies contributing to the background knowledge of this 
thesis were not performed using stroke models. Several of the studies used aspiration 
lesions, which are reproducible but differ in important respects from ischemic injury. For 
example, comparison of aspiration lesions with permanent ischemic models 
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(thermocoagulation of pial vessels overlying the cortex or MCAo) reveals that there are 
differential glucose metabolic responses, differences in gene expression, and different 
amounts of cortical and subcortical plasticity (both axonal and dendritic) depending on 
the model used (Napieralski et al., 1996; Uryu et al., 2001; Gonzalez and Kolb, 2003; Mir 
et al., 2004). Accordingly, in order to best approximate human stroke, ischemic models 
were chosen for the experiments in this thesis. 
1.10 Animal models of stroke: rationale for chapter 4 
Human stroke is very heterogeneous in nature and this is reflected by the 
widespread use of different ischemia models. There are several advantages to using rat 
models of ischemia: rats have a vasculature that closely resembles higher species; they 
are capable of being trained at specific tasks for both cognitive and motor function; the 
size of the brain is well suited for fixation procedures for histological assessment; and 
they are less costly than higher mammals and more acceptable from both ecological and 
ethical perspectives (Ginsberg and Busto, 1989). 
There are two main ischemic models: 1) Global ischemia that is more 
representative of cardiac arrest, and 2) Focal ischemia that targets specific vessels or 
brain regions and is more representative of human stroke due to embolism (blockage by a 
clot formed elsewhere that has moved to the brain) or thrombosis (blockage caused by a 
clot formed at that site). Since the focus of this thesis is the recovery of motor function, 
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focal ischemic models were chosen for the experiments. Several of the most commonly 
used models are discussed below. 
1.10.1 Middle cerebral artery occlusion (MCAo) 
The most commonly used rodent focal ischemia model is transient occlusion of 
the MCA by the introduction of an intraluminal suture (Ginsberg and Busto, 1989; Longa 
et al., 1989; Carmichael, 2005). The suture is introduced through the external carotid 
artery to the internal carotid artery and then into the MCA. This results in immediate 
reduction of blood flow to brain regions supplied by the MCA. This procedure typically 
produces i!Uury to the dorsolateral striatum which occurs early and is largely the result of 
necrosis, and a more delayed infarction of the overlying dorsolateral cortex that is more 
apoptotic in nature (Carmichael, 2005). In addition to the striatum and cortex, this model 
variably also results in injury to the thalamus, cervicomedullary junction, substantia 
nigra, and the hypothalamus, which can cause a variety of deficits (e.g. hyperthermia) 
that are not typical of human MCAo and complicate the model (Dittmar et al., 2003; 
McColl et al., 2004; Carmichael, 2005). 
To create transient ischemia in the MCAo intraluminal model, the suture is 
removed, usually after 60, 90 or 120 min after insertion, and blood flow is immediately 
restored, which may not be typical of most human focal ischemia (i.e. patients not treated 
with t-PA) where reperfusion occurs more gradually as a result of collateralization or 
natural clot lysis (Carmichael, 2005). Other disadvantages of the model include risk of 
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hemorrhage because of vessel wall damage done by the suture, difficulty in feeding after 
the surgery due to lost blood flow to the muscles of mastication, and fluctuations in 
temperature (ifthe hypothalamus is damaged) that would affect infarct size (Carmichael, 
2005). While the MCA is commonly a site of occlusion in humans, in the suture model 
the occlusion duration is often increased (i.e. 10 or 120 min) to reduce variability in 
damage. Unfortunately, this results in such large areas of cortical and striatal injury that 
it may only represent the most severe cases of clinical stroke that are viewed as 
untreatable (Carmichael, 2005). 
1.10.2 Photothrombosis 
Photothrombosis models use photosensitive dyes, such as rose-bengal, to create 
highly circumscribed ischemic lesions in the cortex. The dye is injected intravenously 
and a light source is placed over the exposed skull above the cortical region of interest. 
The light interacts with the dye creating singlet oxygen, which then reacts with lipid 
molecules in the vessel to give rise to platelet aggregation and a clot (Ginsberg and 
Busto, 1989; Carmichael, 2005). Advantages of the model include minimal invasiveness, 
small lesion size, and ability to place the lesion in modality specific regions of the cortex. 
Disadvantages include injury limited to only the cortex since the light cannot reach the 
striatum or other subcortical regions, relatively little penumbra region (potentially 
salvageable tissue), little to no reperfusion, and early extracellular edema that is not 
characteristic of human stroke (Carmichael, 2005). 
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1.10.3 Endothelin-1 
Endothelin-1 (ET -1) is a potent vasoconstrictive peptide that causes constriction 
ofvessels (Yanagisawa et al., 1988). By stereotaxically injecting ET-1 adjacent to the 
MCA, vessel occlusion is achieved without exposing the arteries of the neck, and 
reperfusion is more gradual (taking several hours) and thus more representative of the 
human condition (Biemaskie et al., 2001). By injecting ET-1 in specific brain regions 
(i.e. the cortex or the striatum), small infarcts are produced similar to the 
photothrombosis model but with the advantage of reperfusion. For these reasons, ET -1 
induced focal ischemia was chosen for the experiments described in the subsequent 
chapters. In chapter 2, ET -1 was injected into the cortex and the striatum, effectively 
producing behavioural deficits in several motor tasks. In chapter 3, ET-1 was injected 
adjacent to the MCA also producing behavioural deficits. In the course of the 
experiments for chapters 2 and 3 it was noticed that the success rate (consistency of the 
surgery to result in a behavioural deficit) of the different ET-1 models was quite 
different. This lead to the topic of chapter 4, which is concerned with optimizing the ET-
1 model to produce focal ischemia and sensorimotor deficits for recovery of function 
studies. 
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1.11 Behavioural methods 
1.11.1 Tests of forelimb function 
Approximately 70-80% of stroke patients have an upper-extremity impairment 
(Parker et al., 1986; Nakayama et al., 1994) and as such tests of forelimb function are 
invaluable in studying recovery of function. There are a variety of reaching tests used in 
rodents that include retrieving pellets from narrow tubes (Pisa, 1988), a food tray located 
a distance outside the cage (Whishaw et al., 1986), retrieving pasta that is placed in a 
matrix outside the cage (Ballermann et al., 2001), or shelling sunflower seeds (Whishaw 
and Coles, 1996). All of these tasks can be accomplished with either paw and as a result 
require additional training or restraint mechanisms to ensure the animal consistently uses 
one paw over the other. The staircase test developed by Montoya (Montoya et al., 1991) 
is shown in Figure 1.2. In this test rats are able to retrieve food pellets with either paw 
but they can only retrieve pellets on the right set of stairs with the right paw and vice 
versa, therefore the unimpaired limb cannot be used to compensate for the impaired limb 
after injury. This test is also useful for determining if animals have bilateral deficits. 
Apart from providing a quantitative score of the animal's performance, the staircase test 
also allows detailed observation of reaching dynamics to determine which components of 
a reach are affected (e.g. limb extension, supination etc.) (Clarke et al., unpublished). It 
has also been my experience that animals become proficient at the staircase test more 
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quickly than single pellet reaching and the animals require far less intensive training. For 
these reasons the staircase test was utilized in all three experiments in this thesis. 
Another test of forelimb function used in this thesis is the forelimb asymmetry 
test shown in Figure 1.3. Following injury to the forelimb motor cortex, rats 
preferentially use their non-impaired forelimb for support. When animals are placed in a 
vertical cylinder, which encourages vertical and lateral exploration, instead of using both 
paws more or less equally animals rely primarily on the unimpaired limb (Schallert et al., 
1997). One advantage of this test is that it utilizes innate behaviour and therefore requires 
no training. 
1.11.2 Tests of motor coordination 
While it is obvious to focus on the impaired limb to identify motor dysfunction as 
in the above tests, it is also useful to examine general motor coordination since 
impairments to one limb will affect overall motor function. 
Crossing· a narrow elevated beam normally poses little difficulty for rats and they 
learn the task relatively quickly. Injury to the motor cortex however, results in slips, 
falls, and other foot placement errors. Several studies of motor recovery previously 
mentioned have employed the beam walking test and it was used in chapter 4 of the 
current thesis (Figure 1.4). Previous studies used a rating scale to score the animals and 
showed deficits which tended to spontaneously recover to pre-injury levels (Feeney et al., 
1982; Boyeson and Feeney, 1990; Goldstein and Davis, 1990a). More recently, a more 
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quantitative measure of reporting the number of foot faults after MCAo showed that 
ischemic animals do not recover spontaneously to pre-surgery levels (Biernaskie and 
Corbett, 2001) and this method was employed in this thesis. 
A newer adaptation of the beam walking test is the ladder rung walking test 
(Figure 1.5), in which the rats cross a horizontal ladder with variably spaced rungs. 
Advantages offered by this task include the ability to more closely evaluate the types of 
errors being made, and the ability to change the rung spacing to continue to challenge the 
animal with a new task (Metz and Whishaw, 2002). 
1.11. 3 Choice of rat species 
Both Long-Evans and Sprague-Dawley rats are commonly used for experiments 
involving motor tasks. There is some evidence to suggest that Sprague-Dawley rats are 
less skilled in their qualitative reaching movements compared to Long-Evans rats 
(Whishaw et al., 2003). For this reason Long-Evans hooded rats were originally selected 
for study in this thesis. It is important to note that in Chapter 3 Sprague-Dawley rats 
were used due to differential effects of DSP-4 on the two strains. While DSP-4 depletes 
NE projections from the LC in Sprague-Dawley rats it does not in Long-Evans rats 
(Schuerger and Balaban, 1995) necessitating the change in species for that portion of the 
thesis. 
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1.12 Thesis outline 
1.12.1 Fluoxetine and recovery of motor function after focal ischemia in rats 
This chapter demonstrates that a chronic dose offluoxetine (4 weeks) paired with 
rehabilitative reaching failed to improve motor recovery on a number of behavioural tests 
following ET -1 induced focal ischemia. This chapter is based on the paper "Fluoxetine 
and recovery of motor function after focal ischemia in rats", published in Brain Research 
1044:25-32 (2005) by Windle V and Corbett D. 
1.12.2 Norepinephrine depletionfacilitates motor recovery after focal ischemia in the rat 
This chapter demonstrates that depletion ofNE by injection ofDSP-4 one week 
after ET-1 induced MCAo facilitates motor recovery in various behavioural tests. DSP-4 
treatment facilitated recovery in both standard housed animals as well as those exposed to 
environmental enrichment. This chapter is based on the paper titled "Norepinephrine 
depletion facilitates motor recovery after focal ischemia in the rat", submitted for 
publication to European Journal of Neuroscience (November 2006) By Windle V, Power 
A and Corbett D. 
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1.12. 3 An analysis of four different methods of producing focal cerebral ischemia with 
endothelin-1 in the rat 
This chapter compares four different models of ET -1 induced focal ischemia 
(including the models used in chapters 2 and 3) to produce consistent infarcts as well as 
sensorimotor deficits. The models were evaluated histologically and behaviourally, and 
additionally the cortical + striatal model was evaluated using MR imaging. This chapter 
is based on the paper titled "An analysis of four different methods of producing focal 
cerebral ischemia with endothelin-1 in the rat", published in Experimental Neurology 
201(2):324-334 (2006) by WindleY, SzymanskaA, Granter-ButtonS, WhiteC, BuistR, 
PeelingJ and Corbett D. 
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Table 1.1. Antidepressants used to treat post stroke depression 
Drug 
Increase NE 
Maprotiline 
Reboxetine 
Increase 5-HT 
Trazodone 
Citalopram 
Fluoxetine 
Investigators 
(Dametal., 1996) 
(Rampello et al., 2005) 
(Reding et al., 1986) 
(Andersen et al., 1994) 
(Robinson et al., 2000) 
Outcome 
reduced depression but did 
not improve motor 
recovery 
reduced depression 
improved motor recovery but 
did not reduce depression 
reduced depression 
did not reduce depression 
(Wiart et al., 2000) reduced depression 
(Gainotti et al., 2001) reduced depression and 
improved motor recovery 
(Dam et al., 1996) reduced depression and 
improved motor recovery 
(Fruehwald et al., 2003) reduced depression 
Increase NE and 5-HT 
Nortriptyline (Lipsey et al., 1984) reduced depression 
(Robinson et al., 2000) reduced depression 
(Gonzalez-Torrecillas et al., 1995) reduced depression and 
improved motor recovery 
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Antidepressant Treatment 
............ 
• Inhibit 5-HT orNE 
reuptake or breakdown 
Cf12•.(fependant or 
MAPklnaseoascades Trophic effects: 
synaptic remodeling, 
neurogenesis, 
neuronal survival 
Figure 1.1. Schematic of possible action of chronic antidepressant treatment within the 
brain. Binding of serotonin (5-HT) or norepinephrine (NE) to their various receptors may 
differentially activate different pathways that both result in increased cAMP response 
element binding protein (CREB) and brain derived neurotrophic factor (BDNF). AR = 
adrenoreceptor, PKA =protein kinase A, MAP= microtubule associated protein. 
Adapted from Duman et al., 2001 and Nibuya et al., 1996. 
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Figure 1.2. Staircase reaching test. Animals are placed in a box with a set of staircases 
on either side. Each step holds three food pellets that the animal can only retrieve with 
the paw on the same side as the steps. 
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Figure 1.3. Fore limb asymmetry test. This is an example of an animal with an ischemic 
lesion in the right hemisphere resulting in a deficit of the left forepaw. 
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Figure 1.4. Balance beam test. An impairment of one limb (left forepaw) can result in 
motor coordination deficits seen as errors made with any of the four limbs. 
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Figure 1.5. Ladder-rung walking test. This test requires less training than the beam 
walking test and also allows for observation of more subtle deficits. 
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Chapter 2: Fluoxetine and Recovery of Motor Function After 
Focal Ischemia in Rats 
Published in Brain Research May 2005 
2.1. Introduction 
Stroke is one of the leading causes of permanent disability in the world. The 
focus of stroke research has been on drug treatments that would limit brain damage once 
stroke has occurred. Unfortunately, neuroprotective drug therapy has not been successful 
in reducing injury (De Keyser et al., 1999). Restoration ofblood flow with t-PA (tissue 
plasminogen activator) is most beneficial if given within 3 h of stroke onset, however 
only 20-25% of ischemic stroke patients arrive at hospital within this time frame and 
fewer still are eligible for this treatment (Barber et al., 2001 ). Another problem is the 
heterogeneity of the stroke population, which often limits the effectiveness of a treatment 
to a small subpopulation of patients (De Keyser et al., 1999). Thus, for the majority of 
patients the only option is to rely upon rehabilitation to improve functional recovery and 
quality of life after stroke. Recent experimental evidence suggests that following brain 
injury environmental factors (e.g. environmental enrichment) as well as pharmacological 
and rehabilitative treatment (e.g. amphetamine in combination with training) can 
markedly alter neuronal plasticity and behavioral recovery even when delayed by several 
weeks after the insult in rats (Gladstone and Black, 2000; Biernaskie and Corbett, 2001; 
Biernaskie et al., 2004). 
Many stroke patients suffer from post stroke depression (PSD), a disability that 
affects from 18 to 78 percent of stroke patients (Singh et al., 2000). Several clinical 
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studies have shown PSD correlates with increased disability (Paolucci et al., 2001) and 
hospital stay after stroke (Gillen et al., 2001). Accordingly, many stroke patients are 
given antidepressants that have some actions in common with amphetamine and yet little 
is known as to how these drugs alter recovery of function. Potential side effects limit 
tricyclic antidepressant use in elderly patients and they are not generally prescribed for 
patients with cardiac complications (Robinson, 2003). Thus, fluoxetine (Prozac), a 
selective serotonin reuptake inhibitor, is often prescribed for treating PSD (Paolucci et 
al., 2001; Gupta et al., 2002). Pariente et al. (Pariente et al., 2001) used functional 
magnetic resonance imaging (fMRI) to show that a single dose of fluoxetine alters brain 
activity and modulates motor performance in stroke patients in a use-dependent fashion. 
This was seen as increased activation of the cortex ipsilateral to the injured limb when 
moving the injured index finger, as well as improved performance in a finger tapping test 
and increased grip strength. 
Antidepressants may also improve recovery of function in stroke patients through 
improved mood and motivation to perform rehabilitative tasks. However, a more 
interesting possibility is that antidepressants could have direct effects on brain plasticity 
processes. Several antidepressants, including fluoxetine increase growth factors and 
other proteins associated with plasticity such as brain derived neurotrophic factor 
(BDNF) (Russo-Neustadt et al., 2000; Russo-Neustadt et al., 2001; Coppell et al., 2003) 
and phosphorylated cAMP response element binding (pCREB) protein (Nibuya et al., 
1996), as well as neurogenesis (Malberg et al., 2000; Duman et al., 2001). Amphetamine 
(which has some mechanisms in common with fluoxetine) improves recovery of function 
46 
in rats if it is given in unison with training (Hovda and Fenney, 1984; Stroemer et al., 
1998) and provides benefit in clinical trials when combined with physical therapy or 
motor training (Crisostomo et al., 1988; Walker-Batson et al., 1995; Butefisch et al., 
2002). Based on these amphetamine studies it is likely that training is also required for 
fluoxetine to have a benefit. Stroke patients are given rehabilitation after a stroke, 
therefore in order to mimic the clinical setting the goal of this study was to examine the 
combination of fluoxetine with a rehabilitative reaching task on functional recovery after 
focal ischemia in rats using a battery of sensitive neurobehavioral tests. 
2.2 Materials and methods 
2.2.1 Subjects 
Twenty-nine male Long-Evans rats (Charles River, Montreal, QC, Canada) 
weighing 300-320g at time of initial surgery were used. Subjects were housed in pairs in 
standard Plexiglas cages on a reverse day-night cycle (12 h). Behavioral testing was 
performed during the dark phase. Food and water were provided ad libitum except 
during behavioral testing periods when food was restricted to 12-15 g/day. All 
procedures were in accordance with guidelines set by the Canadian Council on Animal 
Care and approved by the Memorial University Animal Care Committee. 
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2.2.2 Surgery 
Subjects were anesthetized initially with 2 % isoflurane in 30 % oxygen and 70 % 
nitrous oxide and maintained with 1.5 % isoflurane. Animals were placed in a stereotaxic 
frame and a midline skull incision was made. Three small burr holes were made in the 
bone overlying the forelimb and hind limb sensory-motor cortex, and the dorsolateral 
striatum. The vasoconstrictive peptide endothelin-1 (ET-1; 400 pmoll!-1-1 in H20) 
(Calbiochem, Germany) was injected at the following stereotaxic coordinates as 
determined from the Paxinos and Watson Atlas (Paxinos and Watson, 1986): 1. 
anteroposterior (AP) +2.3 mm, mediolateral (ML) +/-2.5 mm, dorsoventral (DV) -2.3 
mm (2.0 !-1-1), 2. AP 0.0 mm, ML +/-2.5 mm, DV -2.3 mm (2.0 ~-tl), 3. AP +0.7 mm, ML 
+/-3.8 mm, DV -7.0 mm (1.0 111) relative to Bregma (all DV measurements were taken 
from the skull surface). This method results in a similar but more restricted lesion than 
the more traditional method of injecting ET -1 adjacent to the middle cerebral artery 
(Sharkey et al., 1994). In the past we have found that due to anatomical variation ofthe 
middle cerebral artery (MCA) in individual rats and accuracy in placing the needle, the 
success rate (percentage of animals that survive the surgery and have a significant deficit) 
with this method is only about 50-60% (Biemaskie and Corbett, 2001; Biemaskie et al., 
2004). In the current study the success rate was 85 %. The lesion was made on the right 
side unless the animal showed a pronounced preference in reaching ability with the right 
forelimb, in which case the animal was lesioned on the left (n = 4). Sham animals 
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received the same surgical procedures up to and including drilling of the burr holes and 
were anesthetized for the same duration as the ischemic animals. Injection of the vehicle 
was not performed in shams because previous studies from our laboratory have shown 
that vehicle injection into the territory of the MCA does not result in behavioural 
abnormalities (Biemaskie and Corbett, 2001; Biemaskie et al., 2004). Temperature was 
monitored and maintained between 36.5 and 37.5 °C using a feedback regulated heating 
blanket (Harvard Apparatus, Holliston, MA) throughout the surgery. 
2. 2. 3 Treatment conditions 
Behavioral assessments (see below) were made on days 5 and 6 after surgery to 
give the animals sufficient time to recover from surgery and begin to regain weight. 
Animals with similar behavioral impairments in reaching were randomly assigned to one 
of four treatment groups. Treatment began on day 7 after ischemia once animals had 
been placed into the various groups. Ischemic + fluoxetine + rehabilitation (I+F+R) 
animals received fluoxetine for 4 weeks as well as 6 h a day of rehabilitation for 4 weeks 
(excluding behavioral testing days) (n = 5). Ischemic+ rehabilitation (I+R) animals 
received the same rehabilitation as the previous group but received only vehicle for 2 
weeks (n = 6). Ischemic (I) animals received only vehicle for 2 weeks (n = 5). Shams+ 
fluoxetine + rehabilitation (Sham) received the same treatment as the ischemic + 
fluoxetine +rehabilitation animals (n = 7). 
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2.2.3.1 Drug treatment 
A maximum dose of 10 mg/kg/day fluoxetine (determined by animal weight at 
time of pump implantation) was delivered via 2-week mini osmotic pumps (2ML2, Alzet, 
Cupertino, CA) subcutaneously implanted between the shoulders while animals were 
aneaesthetized with isoflurane (1.5- 2 %). Implantation occurred on day 7 after 
ischemia. After 2 weeks the pumps were removed and replaced with fresh pumps, so that 
animals received 4 weeks of drug treatment. At the end of the first 2-week treatment 
period animals that received vehicle did not have a second pump implanted in order to 
determine if the pumps or the vehicle were having a negative effect on behaviour. 
Fluoxetine (donated by Eli Lilly, Indianapolis, IN) was dissolved in 50% DMSO (Sigma, 
St. Louis, MO)/H20, and this vehicle was used for animals not receiving fluoxetine. 
After the pumps were removed the remaining fluid was extracted and the volume 
recorded as an approximate measure of pump effectiveness. 
2.2.3.2 Rehabilitation 
Procedur~s for rehabilitation were similar to those described previously 
(Biemaskie and Corbett, 2001). Briefly, beginning on day 7 post ischemia animals were 
exposed for 6 h per day during the week and 3 h per day on the weekends for 4 weeks 
(except on testing days), to a Plexiglas reaching apparatus filled with sugar-rich Noyes 
precision pellets (45 mg, Research Diets Inc, New Brunswick, NJ). The design of the 
apparatus was modified from the staircase apparatus with a central platform and two 
wells on either side that could be filled with pellets. Only the well on the side of the 
impaired limb was filled and the design prevented retrieval of pellets with the non-
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impaired limb and thus encouraged the use of the impaired forelimb. Animals that did 
not receive rehabilitation were fed the average daily intake of the sugar pellets consumed 
by all animals that received rehabilitation ( -16 mg/day). 
2. 2. 4 Behavioral assessment 
Functional recovery was assessed using 3 different behavioral tests. Subjects 
were trained before ischemia on the staircase task for 2 weeks and the ladder-rung test for 
4 days. Animals were retested on all tasks on days 5 and 6 after ischemia and then 2, 4, 
and 6 weeks after the onset of treatment (Figure 2.1 ). 
2.2.4.1 Staircase reaching test (Montoya eta!., 1991) 
This test consists of a chamber with a central platform for the rat to climb onto 
and a set of seven steps on each side. Each step holds three Noyes precision pellets ( 45 
mg, Research Diets Inc, New Brunswick, NJ). The rats remained in the staircase for 15 
min and the total number of pellets eaten on each side was recorded. This test provides a 
sensitive measure of skilled reaching ability of the forepaw, and also of sensory neglect. 
The animals were pre-trained twice per day over a 14-day period. Animals that failed to 
consistently retrieve over 55% of the total available pellets were excluded from the study. 
Animals were retested for two trials per day on days 5 and 6 after ischemia, and any 
animals that showed a mild deficit (;::: 80 % of original score) were excluded from the 
study (n = 3). All remaining animals were tested twice per day for 2 days at each of the 
remainit~g test points. Reaching ability was determined by averaging the score of the 
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impaired limb over the 4 trials and calculating the percentage of pellets eaten compared 
to the average of the last 4 trials prior to stroke. 
2.2.4.2 Forelimb asymmetry test 
Animals were tested for limb preference and their ability to support weight on 
either forelimb by placing the animals in a clear Plexiglas cylinder, 20 em in diameter 
and 35 em high, for 3 min (Schallert et al., 1997). This task measures the number of 
forelimb contacts on the wall as the animal rears to explore the environment. The 
number of bilateral placements, ipsilateral to lesion placements, and contralateral to 
lesion placements were counted. Normal animals tend to use each limb more or less 
equally while ischemic animals favor their ipsilateral forelimb after injury (Schallert et 
al., 1997). The percent of ipsilateral limb use was calculated using the equation: 
ipsilateral contacts/ (ipsilateral + contralateral contacts) x 1 00. Limb contacts were 
videotaped from below using an angled mirror and later analyzed in a blinded fashion. 
2.2.4.3 Ladder-rung walking test 
This task is a sensitive measure of long-term forelimb and hind limb motor 
function as well as motor coordination and compensation after several types of brain 
injury (Metz and Whishaw, 2002). Animals were pre-trained over 4 days to traverse a 
horizontal ladder with evenly spaced rungs. On day 5 and all subsequent test days the 
animals were given one run across the training pattern and then filmed for 4 trials as they 
traversed an irregular rung pattern that varied for each test day. Number of foot slips and 
52 
errors in foot placement were video recorded for a 1.0 m segment of the ladder and the 
average slips and placements per step over the 4 trials were calculated. 
2. 2. 5 Anatomical procedures 
2.2.5.1 lfistolo~ 
At the completion of the study animals were overdosed with Somnotol® and 
transcardially perfused with heparinized saline followed by 4 % paraformaldehyde. 
Brains were removed and post-fixed over night before being placed in a solution of20% 
sucrose in phosphate buffered saline (PBS), and allowed to sink (approximately 3 days). 
Brains were rapidly frozen using dry ice and sectioned using a cryostat (CM 3050 S, 
Leica, Germany) at 40 !J.m. Every gth slice was mounted and stained using Cresyl Violet. 
2.2.5.2 Infarct measurement 
Using a random start point, sections stained with Cresyl Violet from +3.0 mm to-
2.5 mm relative to Bregma were assessed for injury using NIH image software. The 
same number of sections were analysed for each animal. Remaining non-injured tissue in 
the cortex and striatum of both hemispheres was measured and the area of the healthy 
tissue in the ipsilateral side was subtracted from the healthy tissue in the contralateral side 
to give an area of injured tissue in the cortex and striatum separately. Total volume of 
injury was calculated by averaging the area recorded from each slice, and multiplying 
that value by the total distance between the first and last slices that contained injured 
tissue. 
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2. 2. 6 Statistics 
Behavioral data were analyzed using repeated measures ANOV A or two-way 
ANOVA where appropriate. To determine differences between groups Fisher's test or 
Student's t-test comparisons were used. 
2.3 Results 
2. 3.1 Fluoxetine administration 
All pumps were examined for defects after removal and remaining fluid was 
extracted and measured. One animal was discarded (I+F+R) due to pump malfunction. 
On average 0.4 ml of the initial2.0 ml of drug solution remained. Adjusting for animal 
weight gain and amount of fluid pumped, the average dose of fluoxetine was calculated 
to be 9.0 mg/kg/day ± 0.82 for the first set of pumps and 8.95 mglkg/day ± 0.96 for the 
second set of pumps. No difference was found between the amount of fluoxetine 
delivered to the ischemic and control animals (data not shown). 
2. 3. 2 Infarct measurement 
Brain tissue from all animals included in the behavioral results was assessed to 
determine if treatment had any effect on infarct size. Figure 2.2 depicts the areas 
typically injured by the ET-1 protocol used for this study. The injured area included the 
forelimb region of the sensorimotor cortex and a portion of the dorsolateral striatum. The 
54 
average volume for injured tissue in the cortex, striatum and combined values are given 
in Table 2.1. There was a trend for the I+R+F group to have a larger infarct than the 
other two ischemic groups, but there was greater variability in the I+R+F group and no 
effect of treatment was found for the amount of cortex (F(2,IJ) = 0.376, p = 0.6935), 
striatum (F(2,13) = 1.065, p = 0.3728) or total (cortex+ striatum) tissue (F(2,13) = 0.511, p = 
0.6116) injured. Regression analysis revealed that the volume of injury did correlate with 
increased impairment on the staircase test (r = 0.784, p < 0.0001), both slips/step (R = 
0.575, p = 0.0051) and placement errors/step (r = 0.585, p = 0.0043) of the ladder test, 
but not the forelimb asymmetry test (r = 0.338, p = 0.1235) at the first test point after 
ischemia. 
2.3.3 Staircase reaching test 
A repeated measures ANOVA revealed a significant effect of treatment (F(3,19) = 
8.993, p = 0.0006) and an effect of day (F(3,I9) = 11.315, p < 0.0001). As shown in 
Figure 2.3, Fisher's PLSD post hoc analysis revealed that ischemic injury resulted in a 
significant decrease in performance in all ischemic groups compared to shams that 
persisted throughout the experiment (p < 0.01). No differences were found between the 
different ischemic groups and none of these groups improved over time. Effect of day 
was due to Shams (as determined by paired t-test) at 2 and 4 weeks treatment having 
lower scores compared to pre-treatment (p < 0.01 for both). Despite this there was no 
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difference between time points for Shams by the end of the study compared to pre-
treatment levels of performance. 
2.3.4 Forelimb asymmetry test 
An effect of group was found in the cylinder task (F(3,19> = 3.925, p = 0.0245), as 
well as an effect of day (F (3, 19) = 1 0.189, p < 0. 001 ). Fisher's test showed that all ischemic 
groups increased the number of ipsilateral contacts relative to sham animals immediately 
after surgery (p < 0.01) but returned to levels comparable to shams after 2 weeks (Figure 
2.4). I+F+R and I+ R animals showed a significant difference from sham animals after 4 
weeks of treatment but they were not significantly different at 2 weeks of treatment or 2 
weeks after treatment ended and were not different from other ischemic groups. Paired 
student's t-tests revealed that while sham animals did not significantly differ between 
time points all ischemic animals remained impaired compared to their pre-surgery score 
at the final test point (data not shown, p < 0.05). 
2.3.5 Ladder-rung walking test 
There was an effect of group for slips/step (F(3,I9) = 3.744, p = 0.029) but not for 
day (F(3,I9) = 0.368, p = 0.7763). The I+F+R group was significantly more impaired than 
the sham group after 2 weeks of treatment (p < 0.05) but at no other time point. The I+ 
R group was significantly different from sham animals at pre-treatment as well as after 2 
weeks of treatment (p < 0.05 and 0.01 respectively). In contrast the I group lacking any 
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treatment was not different from the sham group (Figure 2.5a). Paired student t-test 
showed that none of the groups improved over time compared to pre-treatment scores. 
For placement errors/step there was no effect of group (F(3,19) = 1.261, p = 0.3159) but 
there was an effect of day (F(3,I9) = 37.836, p < 0.0001). All groups improved over time 
as determined with student t-test (p < 0.05). The I + R group improved significantly from 
pre-treatment to 2 weeks treatment (p = 0.05), while all other groups did not reach 
significance until4 weeks of treatment (Figure 2.5b). 
2.4 Discussion 
In the current study the goal was to combine chronic fluoxetine treatment with 
rehabilitation to approximate treatment of stroke patients in a clinical setting. In our 
previous work we have observed benefit of the rehabilitation task used in the present 
study when it is combined with environmental enrichment (Biemaskie and Corbett, 2001; 
Biemaskie et al;, 2004). In this study rehabilitation (i.e. reach training) alone did not 
improve the functional outcome of ischemic animals with or without combined fluoxetine 
treatment. This differs from studies in monkeys where reach training alone facilitates 
recovery (Nudo et al., 1996b ). It is possible that environmental enrichment is a necessary 
component in rodent models of stroke that must be given concurrently with this type of 
reach training in order for the dendritic plasticity and the behavioral benefits to occur 
(Schallert et al., 2000). Combining fluoxetine with rehabilitation was also done because 
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previous animal studies have shown that amphetamine and related agents only enhance 
recovery when administered at the same time as the behavioral task (Hovda and Fenney, 
1984; Stroemer et al., 1998). It is also conceivable that the reason fluoxetine fails to 
improve functional recovery while environmental enrichment and amphetamine are 
beneficial is that different mechanisms are involved. It is thought that the main benefit of 
amphetamine is due to increased norepinephrine (NE) transmission (for a review see 
(Gladstone and Black, 2000)) and environmental enrichment has also been shown to 
increase brain levels ofNE in the mouse (Naka et al., 2002). The main action of 
fluoxetine is to increase serotonin transmission with little effect on NE (Beyer et al., 
2002). 
Fluoxetine has been suggested to improve motor recovery in humans after stroke 
(Dam et al., 1996; Pariente et al., 2001 ). In spite of these clinical findings, no 
improvement on a range of tests of long-term sensorimotor function was found in the 
present study nor in a related study by Jolk.konen and colleagues (Jolk.konen et al., 
2000a). The study by Jolk.konen et al., (Jolkkonen et al., 2000a) used a smaller dose of 
fluoxetine (5 mglkg/day) given over a shorter time period (10 days) and did not employ a 
rehabilitation task. The present study found that fluoxetine did not improve recovery of 
function of forelimb reaching, forelimb preference or motor coordination while the 
Jolkkonen study found that fluoxetine failed to improve performance on limb placement 
and a cognitive water maze task (Jolkkonen et al., 2000a). It is possible that acute versus 
chronic administration of fluoxetine has different molecular effects. Differences such as 
these may explain the results in the acute clinical imaging study, which found that a 
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single dose of 20 mg of fluoxetine alters brain activity and modulates motor performance 
in stroke patients (Pariente et al., 2001) whereas the animal studies have found no 
alteration in performance. For example, fluoxetine can either increase or decrease levels 
of cAMP, CREB, BDNF and its receptor, tyrosine receptor kinase (trk)B, mRNA 
depending on whether an acute, short-term, or prolonged dose is given (Nibuya et al., 
1996; Miro et al., 2002; Coppell et al., 2003). 
Fluoxetine in a dose of 1 0 mg/kg/day has previously been shown to increase 
serotonin levels in the rat brain (Felton et al., 2003) as well as increase BDNF gene 
expression within the hippocampus when given for 2 weeks (Coppell et al., 2003), 
therefore it is unlikely that our dosing regimen was insufficient to produce changes in 
BDNF. Increases in BDNF and its trkB receptor have been positively correlated with 
increases in synapsin I (a protein involved in transmitter release) as well as GAP-43 
(Gomez-Pinilla et al., 2002). These and other studies (Jin et al., 2002; Vaynman et al., 
2003) suggest a role for BDNF in neurite outgrowth and plasticity and that by acting 
through BDNF, fluoxetine may also affect neural plasticity. However, several studies 
report opposing results with 2-week fluoxetine dosing on BDNF levels in the 
hippocampus. For example, Nibuya et al. (Nibuya et al., 1996) and Coppell et al. 
(Coppell et al., 2003) note increased BDNF while Mir6 et al. (Miro et al., 2002) reported 
decreased BDNF. Differences in dosing regimens may account for these discrepancies, 
but it is evident that effects of fluoxetine on BDNF levels require further investigation. It 
is possible that the benefits of fluoxetine could be masked if the presence of the pumps 
interfered with the animals' performance (i.e. impaired limb use) on the behavioral tasks. 
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This is an unlikely explanation for our results since there was no increase in recovery of 
ischemic animals that received vehicle once their pumps were removed after 2 weeks of 
treatment. It is more likely that despite effects of fluoxetine on BDNF they are 
insufficient to augment neural plasticity. A study that compared exercise-induced 
increases in BDNF found that lesioning the noradrenergic but not the serotonergic system 
attenuated the increases in BDNF normally seen with 7 days of wheel running. This 
suggests that the serotonergic system plays a minimal role in BDNF regulation (Garcia et 
al., 2003). Wheel running for 7 days increases BDNF levels by 200% in the dentate 
gyrus of the hippocampus (Garcia et al., 2003), whereas 2 weeks offluoxetine treatment 
(10 mg/kg) only increases BDNF levels by about 125% in the same region (Coppell et 
al., 2003). Antidepressants with a greater impact on the noradrenergic system may 
enhance BDNF to a greater extent than fluoxetine. 
Another interpretation of the results from clinical studies suggesting that 
fluoxetine enhances the recovery process after stroke (Dam et al., 1996; Pariente et al., 
2001) is that the benefit is due to alleviation of depression. Since depression is a 
predictor of worsened outcome (Paolucci et al., 2001) it is possible that by improving 
depressive symptoms patients would achieve a higher level of recovery simply because 
they were more motivated to engage in rehabilitation. In this and other animal studies 
depressed mood is unlikely to be a confounding factor. Indeed motivation is often 
provided as a result of mild food deprivation (e.g. staircase test) and other incentives (e.g. 
escaping ladder to return to home cage). Therefore, in the absence of depressed mood, 
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fluoxetine does not appear to have the capacity to promote processes of neuronal 
plasticity and functional recovery. 
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Table 2.1. Infarct volume (mm3) 
Cortex 
I 
I+R 
I+R+F 
20.4 ± 7.4 
15.38 ± 4.0 
28.22± 17.6 
Striatum 
10.12 ± 1.99 
12.53 ± 2.6 
17.1 ± 4.9 
Total 
30.54 ± 8.9 
27.92 ± 4.5 
45.32 ± 21.8 
Infarct volume did not differ between any of the groups. Values are mean± SEM. 
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Figure 2.1. Time line of experiment. Days 5,6 correspond with pre-treatment testing and 
the remaining test points correspond with 2 weeks treatment, 4 weeks treatment and 2 
weeks post-treatment respectively. At all test points ladder-rung walking was tested on 
the first day and forelimb asymmetry on the second day. Staircase was tested over two 
trials each of the test days and the average over the 4 trials was used as the animals score 
at each test point. 
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Figure 2.2. Representative diagram of regions of infarct after combined cortical and 
striatal injections of ET -1. Measurements given are in mm relative to Bregma. 
64 
~ I+ F+ R 
D I+ R 
' llill I 
• Sham w 
U) 
+I 100 ~ 
CJ) 
~ 
::l 
tA 
I 80 ~ 
Q. 
0 
..... 
, ** * * * ~ 60 ftS * Q. 
E 
0 (,) 
c 40 
.! 
ftS 
CJ) 
~ 
a; 20 
a. 
'?/!. 
0 
Pre-treat 2wks Treat 4wks Treat 2wks Post 
Figure 2.3. Staircase test of skilled forelimb reaching. All ischemic groups were 
significantly impaired compared to sham animals at all time points but no difference was 
found between the treatment groups. Values presented are mean ± SEM (* indicates a 
significant difference from sham group, p < 0.01, ** p < 0.001). 
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Figure 2.4. Forelimb asymmetry task. This task measured the number of ipsilateral 
forelimb contacts compared to contralateral contacts while the animal reared in a 
cylinder. All ischemic animals showed an increase in ipsilateral forelimb use after the 
ischemia (i.e. pre-treatment), but no difference was found between the treatment groups. 
Values presented are mean ± SEM (* indicates a significant difference from sham group, 
p < 0.05, ** p < 0.01). 
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Figure 2.5. Ladder-rung walking test. A. Foot slip errors/step decreased similarly for 
each treatment group. Although ischemic animals differed from shams at early time 
points they did not change significantly from themselves over time. (* indicates a 
significant difference from sham group, p < 0.05, ** p < 0.01) B. Placement errors/step 
revealed that animals improved at this task regardless of treatment group. Values 
presented are mean ± SEM. 
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Chapter 3: Norepinephrine Depletion Facilitates Recovery of 
Function After Focal Ischemia in the Rat 
Submitted to European Journal of Neuroscience November 2006 
3.1 Introduction 
Stroke is one of the leading causes of permanent disability in the world and as 
such research and therapy aimed at improving functional recovery after stroke is of the 
utmost importance. It is becoming apparent that traditional physiotherapy practices can 
be improved upon and recent experimental evidence suggests that following brain injury 
environmental factors (e.g. environmental enrichment) as well as pharmacological and 
rehabilitative treatment (e.g. amphetamine in combination with training) can markedly 
alter neuronal plasticity and behavioural recovery even when delayed by several weeks 
after an ischemic insult in rats (Gladstone and Black, 2000; Biemaskie and Corbett, 2001; 
Johansson and Belichenko, 2002; Biemaskie et al., 2004). 
Amphetamine has shown promise as an agent to improve motor recovery after 
brain injury as early as 1946 (Feeney, 1997; Gladstone and Black, 2000; Feeney et al., 
2004). A single dose of amphetamine, and more effectively several doses paired with 
motor training, promotes recovery of function on a beam walking task in cats as well as 
rats after brain injury (Feeney et al., 1982; Hovda and Fenney, 1984; Goldstein and 
Davis, 1990). The beneficial effects of amphetamine can be blocked by haloperidol, a 
dopamine (DA) D2 receptor antagonist, suggesting that the action may be mediated by 
DA (Feeney et al., 1982). However, amphetamine also increases serotonin (5-HT) and 
norepinephrine (NE) levels in the brain in addition to DA and other studies suggest that 
72 
the noradrenergic system is most likely responsible for the positive actions of 
amphetamine on recovery. For example, intraventricular infusion ofDA orNE both 
improve beam walking after cortical injury, but if the DAis administered with a 
dopamine beta hydroxylase (Dj3H) inhibitor to block conversion toNE the effect is lost, 
demonstrating the importance ofNE (Boyeson and Feeney, 1990). In addition, 
atipamezole (an alpha-2 adrenergic antagonist that increases NE) facilitates sensorimotor 
recovery after middle cerebral artery occlusion (MCAo) in the rat (Jolkkonen et al., 2000; 
Butovas et al., 2001; Puurunen et al., 2001). Finally, a number of drugs that increase NE 
facilitate motor recovery after brain injury, and depleting or blocking NE can attenuate 
recovery or reinstate deficits in recovered animals (Gladstone and Black, 2000). 
We have previously found that environmental enrichment improves forelimb 
motor function after MCAo (Biemaskie and Corbett, 2001) and others have shown that 
mice reared in an enriched environment for 40 days had significantly higher brain levels 
ofNE than control animals while 5-HT and DA levels were unchanged (Naka et al., 
2002). Environmental enrichment facilitates neuroplasticity, neurogenesis and increases 
several neurotrophins, such as brain derived neurotrophic factor (BDNF) in the 
hippocampus and cortex, which may explain why it facilitates recovery of motor function 
after brain injury (Pham et al., 1999; Ickes et al., 2000; Biemaskie and Corbett, 2001; 
Johansson and Belichenko, 2002; Mohammed et al., 2002; Gobbo and O'Mara, 2004). 
Similarly, amphetamine and other drugs that increase NE have also been shown to 
facilitate plasticity, neurogenesis and neurotrophin increases (Stroemer et al., 1998; 
Malberg et al., 2000; Russo-Neustadt et al., 2001; Butefisch et al., 2002). Prazosin (an 
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alpha-1 adrenergic blocker) decreases training dependant brain plasticity in humans 
(Sawaki et al., 2003) and depleting NE with N-(2-chloroethyl)-N-ethyl-2-
bromobenzylamine (DSP-4) has also been shown to block BDNF increases associated 
with exercise (Garcia et al., 2003). 
The locus coeruleus (LC), the largest nucleus of noradrenergic neurons in the 
central nervous system, is the origin of the majority of noradrenergic afferents in the 
CNS, which project widely throughout the brain (Nakamura and Sakaguchi, 1990). 
These noradrenergic projections have the capacity to regenerate and have been shown to 
be plastic in response to stress and brain injury (Nakamura and Sakaguchi, 1990). In 
addition, infusion of antidepressants (several have been suggested to increase functional 
recovery after brain injury) increases NE axonal regeneration after a 6-0HDA lesion of 
NE axons in the frontal cortex (Nakamura, 1991). Lesioning of the LC prior to motor 
cortex injury impairs motor recovery on the beam walking task in rats (Goldstein and 
Bullman, 1997) and selective degeneration of the NE projections from the LC using DSP-
4 also impairs motor recovery (Goldstein et al., 1991; Boyeson et al., 1992). 
Despite data supporting the importance ofNE in recovery of function after brain 
injury it is important to note that most of these studies have been performed using drugs 
(i.e. amphetamine, antidepressants and prazosin) that are known to have effects on other 
neurotransmitters in addition to NE. In those studies that lesioned the NE system it is 
also important to note that the NE lesions were performed prior to the motor cortex 
injury, and there are conflicting data about whether depleting NE increases or decreases 
subsequent ischemic injury (Blomqvist et al., 1985; Nishino et al., 1991; Nellgard et al., 
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1999a). Increasing NE may facilitate motor recovery but it has yet to be determined 
whether NE is actually required to promote or increase recovery after ischemia. In order 
to more directly assess the involvement ofNE in functional recovery, the present study 
used DSP-4 to selectively deplete NE projections from the LC one week after MCAo in 
rats. Environmental enrichment combined with a rehabilitation task was used to promote 
recovery and three different sensorimotor tests were used to determine if DSP-4 impeded 
recovery. In addition, BDNF was measured in a subset of animals to determine if 
depleting NE had any effect on levels of this neurotrophin. 
3.2 Materials and methods 
3.2.1 Subjects 
A total of 139 male Sprague Dawley rats (Charles River, Montreal, QC, Canada) 
weighing approximately 300 gat time of surgery were used in this study. Initially, all 
animals were socially housed in pairs in standard Plexiglas cages on a reverse day-night 
cycle (see housing and treatment groups below). Behavioural testing was performed 
during the dark phase. Food and water were provided ad libitum except during 
behavioural testing periods when food was restricted to 12-15 g/day. All procedures 
were in accordance with guidelines set by the Canadian Council on Animal Care and 
approved by the Memorial University Animal Care Committee. Every effort was made 
to reduce animal numbers and alleviate suffering. 
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3.2.2 Surgical procedures 
Animals were anesthetized with 3 % isoflurane in 30 % oxygen and 70 % nitrous 
oxide and were maintained with 1.5% isoflurane. Temperature was maintained between 
36.5° C and 37.5° C throughout the surgery using a self-regulating heating blanket 
(Harvard Apparatus, Holliston, MA). Animals underwent Endothelin-1 (ET -1) MCAo as 
outlined in previous studies (Biemaskie and Corbett, 2001) except an increased 
concentration of ET-1 (human and porcine from Calbiochem, Cedarlane, Hornby, ON, 
Canada) was employed. Briefly a single injection ofET-1 (600 pmol in 3 ~-tl sterile H20) 
was placed adjacent to the MCA: anterioposterior (AP) +0.9 mm, mediolateral (ML) -5.2 
mm and dorsoventral (DV) -8.7 mm. All stereotaxic measurements are relative to Bregma 
(Paxinos and Watson, 1986). The control group included sham animals that underwent 
the same surgery up to and fncluding the drilling of the burr hole but did not receive ET-
1. Due to a relatively low success rate (- 60 %) with this ischemic model (Biemaskie et 
al., 2004) animals with unsuccessful ischemia (as determined by behavioural and later 
histological assessment) were included in the control group in order to reduce animal 
numbers. 
3.2.3 Norepinephrine depletion 
In order to deplete the noradrenergic projections from the LC, rats were given a 
single I.P. injection of 50 mg/kg ofDSP-4 dissolved in sterile saline (50 mg/ml) 6 days 
after ischemia. Dose ofDSP-4 was based on previous studies that have shown long-term 
depletion ofNE (Ross, 1976; Fritschy and Grzanna, 1991). Animals were closely 
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monitored and given mash and lactated ringers (5 ml) if needed. Most animals appeared 
healthy and were able to commence their housing treatment (see below) the next day, 
however a small number of animals were kept separate until they began to gain weight 
(usually 2-3 days). Weight loss occurred equally in all the treatment groups and the 
slight delay in starting housing treatment did not affect outcome (data not shown). · 
Animals that did not receive DSP-4 received an equivalent volume (1 ml/kg) of sterile 
saline. 
3.2.4 Housing and treatment groups 
A timeline of the experimental protocol is given in Figure 3.1. Five days after 
ischemia rats were tested on 3 behavioural tests of motor coordination and forelimb 
function (see below), grouped according to the severity of impairment and randomly 
assigned to one of eight treatment groups: ischemic + enriched rehabilitation (I + ER), 
ischemic+ standard housing (I + St), Control + ER, Control + St, I + ER + DSP-4, I + St 
+ DSP-4, Contr~l + ER + DSP-4, Control + .St + DSP-4. Post-treatment testing was 
carried out 2, 6 and 9 weeks after the injection ofDSP-4 and start of housing treatment. 
In addition to the animals listed in the above groups 30 animals in the 4 ischemic groups 
(n = 7-8 per group) were used without behavioural testing for the BDNF portion of the 
study and 7 animals in the I + ER + DSP-4 and 6 animals in the I + St + DSP-4 group 
were tested behaviourally but sacrificed one week post DSP-4. 
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3.2.4.1 Enriched rehabilitation 
A similar protocol was followed as used previously (Biemaskie and Corbett, 
2001 ). Animals were housed in groups of 6-8 rats in large metal cages equipped with 
ropes, beams, platforms and various toys. The groups switched cages twice a week at 
which point the cages were cleaned and the types of toys and the orientation of objects 
were changed. In addition, animals were given a 6 h rehabilitation session 5 days a week 
(with the exception of testing days) for a total of9 weeks. The animals were placed 
individually in a standard cage containing a Plexiglas reaching apparatus containing 
Noyes precision pellets ( 45mg, Research Diets Inc, New Brunswick, NJ). The design of 
the apparatus was modified from the staircase apparatus with a central platform and two 
wells on either side that could be filled with pellets. Only the well on the side of the 
impaired limb was filled and the design prevented retrieval of pellets with the non-
impaired limb and thus encouraged the use of the impaired forelimb. Animals that failed 
to consistently obtain over 5 g of pellets per day were excluded from the study. 
3.2.4.2 Standard housing 
Animals were housed in pairs in standard Plexiglas cages. In addition to their 
regular chow they were fed the average amount of Noyes pellets eaten by the ER rats 
each day (approximately 12-14 g). 
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3.2.5 Behavioural assessment 
3.2.5.1 Staircase reaching test (Montoya et al., 1991) 
This test consists of a chamber with a central platform for the rat to climb onto 
and a set of seven steps on each side. Each step holds three 45 mg Noyes precision 
pellets. The rats remained in the staircase for 15 min and the total number of pellets 
eaten on each side was recorded. This test provides a sensitive measure of skilled 
reaching ability of the forepaw, and also of sensory neglect. The animals were pre-trained 
twice per day over a 14-day period ending 2 days prior to ischemic surgery. Animals that 
failed to consistently retrieve over 55% of the total available pellets were excluded from 
the study. Animals were retested for two trials per day on days 5 and 6 after ischemia 
(pre-treatment), as well as over two days 2, 6 and 9 weeks after DSP-4 (post-treatment). 
Reaching ability was determined by averaging the score of the impaired limb over the 4 
trials and calculating the percentage of pellets eaten compared to the average of the last 4 
trials prior to ischemia. 
3.2.5.2 Forelimb asymmetry test 
Animals were tested for limb preference and their ability to support weight on 
either forelimb by placing the animals in a 20 em diameter x 3 5 em high clear Plexiglas 
cylinder for 5 min (Schallert et al., 1997). As the animal rears to explore the environment 
the number of bilateral paw placements, placements of the paw ipsilateral to the lesion, 
and placements of the paw contralateral to lesion are counted. Animals were required to 
have a minimum of 20 contacts. If 20 contacts were not achieved in the 5 min time frame 
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the animal was observed until20 contacts had been made. Normal animals tend to use 
each limb more or less equally while ischemic animals favour their ipsilateral forelimb 
after injury (Schallert et al., 1997). The percent of ipsilateral limb use was calculated 
using the equation: (ipsilateral contacts+ lh bilateral contacts/ total contacts) x 100. Paw 
contacts were videotaped from below using an angled mirror and later analyzed in a 
blinded fashion. Animals were tested once prior to ischemia and once at each subsequent 
time point. 
3.2.5.3 Ladder-rung walking test 
Animals were tested for forelimb and hindlimb function as well as motor 
coordination by crossing a ladder with an irregular rung pattern (Metz and Whishaw, 
2002). Animals were trained to cross the ladder over 4 trials in one day. At each test 
point, including prior to ischemia, the animals were filmed while crossing the ladder on 4 
trials. Slips and misplacements of paws were scored for a 1m segment of the ladder. To 
give an indication of impairment the number of slips were added to the placement errors 
and divided by the number of steps taken for a total number of errors/step. The rung 
pattern was changed for each test point. 
3.2.6 Histological procedures and assay 
3.2.6.1 Histolo~ 
Animals were sacrificed either at 1 or 9 weeks post-DSP-4 treatment. At the 
conclusion of each study, animals were injected with an overdose of Somnotol® and 
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perfused transcardially with heparinized saline followed by 4 % paraformaldehyde for 5 
min. Brains were removed and placed in 4 % paraformaldehyde for 90 min then 
transferred to a 20 % sucrose solution in phosphate buffered saline (PBS) and allowed to 
sink (approximately 3 days). Brains were frozen on dry ice and 40 f!m sections were cut 
using a cryostat (CM 3050 S, Leica, Germany). Every gth section was mounted and 
stained with Cresyl Violet for infarct volume assessment. All other sections were stored 
in cryoprotectant at - 20 °C until processed for immunohistology. 
3.2.6.2 Infarct measurement 
Slides were scanned and every third slice was analyzed microscopically and the 
healthy tissue in the cortex, striatum and total hemisphere for each side of the brain were 
traced using Image J software (NIH). Volume of injury was calculated by subtracting the 
area measured in the ischemic hemisphere from the contralateral hemisphere and 
multiplying that value by the distance between the measured slices. 
3. 2. 6. 3 Immunohistology 
Every gth section was stained for D~H. Sections were washed in PBS followed by 
3 min in 3 % H20z. Slices were then washed in PBS (3 x I 0 min), incubated in 5 % 
normal goat serum in PBS with 0.25% triton-X for I hand then incubated overnight at 4 
°C in 1 :IOOO dilution of mouse anti- D~H (Chemicon, Temecula, CA, USA) in PBS with 
0.25% triton-X. The next day slices were washed in PBS, incubated in 1:500 dilution of 
biotinylated goat anti-mouse (Jackson Immuno Research Labratories Inc., West Grove, 
PA, USA) in PBS with 0.25 % triton-X for I h, washed in PBS, incubated in I 0 ~-tg/ml 
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Extravadin (Sigma-Aldrich, St. Louis, MO, USA) in PBS with 0.25% triton-X washed in 
PBS and reacted for 5 min in 3,3 '-Diaminobenzidine (DAB) tablet set (Sigma-Aldrich, St. 
Louis, MO, USA). Negative controls were run with each batch of staining. 
3. 2. 6. 4 Measurement of Df3H staining 
Neuronal projections stained with D(3H were traced and analyzed with 
Neurolucida software (MicroBrightfield Inc., Williston, VT, USA) at 40X magnification 
(Leica DMRXE light microscope, Leica Microsystems Canada, Richmond Hill, ON, 
Canada). The total length of axonal projections in a given area was calculated using 
Neuroexplorer (MicroBrightfield Inc., Williston, VT, USA). Projections were analyzed 
in 4 different regions of interest (ROI) in the contralateral hemisphere from the MCAo (in 
order to avoid infarcted tissue): the frontal cortex (ROI 1), the forelimb region of the 
motor cortex (ROI 2), the parietal cortex (ROI 3) and CAl region of the hippocampus 
(ROI 4). Three counts where taken in each ROI (150 X 150 ~m2) and averaged. Figure 
3.6 shows the location of each ROI. 
3.2.6.5 BDNF immunoassay 
Animals in this portion of the study were sacrificed by decapitation at 9 weeks 
under light isoflurane anesthesia. Both hippocampi and a portion of motor cortex from 
the intact, contralateral hemisphere (to avoid infarcted tissue) were quickly removed, 
weighed and flash frozen in liquid nitrogen. Samples were stored at -80 °C until further 
processing. Tissue was homogenized in a 7 times volume of ice-cold homogenization 
buffer (lOOmM Tris/HCl, pH 7, containing 2% bovine serum albumin, IM NaCI, 4mM 
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EDTA, 2% Triton X-100, 0.1% sodium azide and protease inhibitor cocktail (Sigma-
Aldrich, St. Louis, MO, USA) and centrifuged at 15,000 x g for 30 min at 4 °C. 
Supernatants were collected and further diluted with buffer for a final dilution of 70 
times. Samples were frozen and stored at -20 °C until processed further. BDNF levels 
were measured using ELISA (Chemicon, Temecula, CA, USA) according to 
manufacturer's protocol. Using the optical densities of known BDNF concentrations to 
create a standard curve the mean optical densities of samples (in duplicate) were used to 
calculate BDNF concentrations. Each plate contained samples from all four groups 
tested in this portion of the study. 
3. 2. 7 Statistics 
Behavioural and histological data were analyzed using repeated measures 
AN OVA or two-way AN OVA where appropriate. A Fisher's PLSD test was used to 
determine differences between groups and Student's-t test to determine differences within 
groups over time, where p < 0.05 was considered significant. Regression analysis was 
used to determine the relationship between the amount of Dj3H staining and staircase 
performance. All values given are mean ± SEM. 
3.3 Results 
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3.3.1 Infarct volume 
Values for infarct volume are provided in Table 3.1. There was no effect ofDSP-
4 or housing on infarct volume although there was a trend for animals in the ER groups to 
have smaller cortical, and thus total, infarcts. The area of injury was typical for MCAo 
and Figure 3.2 shows the range of injury in damaged animals. 
3.3.2 Behavioural results 
No differences were found between control animals with regard to housing 
condition or drug treatment therefore they were pooled into a single control group. Six 
animals that had shown minimal deficits in staircase testing early post-stroke were later 
eliminated from the control group because of ischemic injury. Another 9 animals were 
eliminated because they failed to reach the criteria for reaching success in rehabilitation 
or they continued to drop weight 4 days after DSP-4 treatment. The final group numbers 
were I+ ER (n = 13), I+ St (n = 14), I+ ER + DSP-4 (n = 12), I+ St + DSP-4 (n = 14) 
and control (n =. 16). 
3.3.2.1 Staircase reaching test 
There was a significant effect of group (F(4,64) = 28.064, p < 0.0001), time (F(3,64) 
= 7.831, p < 0.0001) as well as a significant timex group interaction (Foz,64) = 2.447, p = 
0.005). All ischemic groups were severely impaired in the staircase test compared to 
control animals at all time points (p :::::; 0.0008). While the I + St group did not improve 
over the 9 weeks the I + ER group improved slightly and the two DSP-4 treated groups 
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improved significantly (p < 0.05) from pre-treatment (Figure 3.3). The I +ER + DSP-4 
group improved the most and showed significantly better recovery than the I + St group 
from 2 weeks post-DSP-4 treatment on (p :S 0.01). At 9 weeks post-treatment bothER 
groups as well as the I+ St + DSP-4 group exhibited significantly better recovery than 
the I+ St group (p :s 0.01). 
3.3.2.2 Forelimb asymmetry test 
There was no overall effect of group for this test although all ischemic groups 
were significantly impaired compared to control animals 6 days after ischemia (pre-
treatment) (p < 0.001). There was an effect of time (F(3,64) = 6.999, p = 0.0002) with all 
of the ischemic groups improving so that at 9 weeks no groups were different from the 
control group. Although all groups showed recovery on this task the I + St group was the 
slowest to recover, returning to control levels at 6 weeks rather than at 2 weeks like the 
other ischemic groups (Figure 3.4). 
3.3.2.3 Ladder-rung walking test 
There was no effect of group for this task but there was an effect of time (F (3,64) = 
48.319, p < 0.0001). All groups improved over the course of the study reducing the 
number of errors/step (Figure 3.5A). Comparison of errors/step at 9 weeks to pre-
treatment performance showed that all groups made significant improvements but the two 
ER groups made the greatest gains (p < 0.05 for the St groups and controls, p < 0.0001 
for the ER groups) (Figure 3.58). 
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3.3.3 l)j1Jlstainin~ 
Figure 3.6 illustrates Dj3H terminal staining in a DSP-4 and a saline treated 
animal. There was a significant effect of group (F(s,63) = 15.009, p < 0.0001), the region 
of interest measured (F(3,63) = 105.776, p < 0.0001) as well as group x region interaction 
(F(ls,63) = 5.612, p < 0.0001) for Dj3H staining. All groups that received DSP-4 showed 
significantly decreased staining for Dj3H compared to the groups that received saline (p < 
0.01) (Figure 3. 7 A). There was no effect of ischemia or housing on the amount of Dj3H 
staining although there was a trend for the I + ER + DSP-4 group to have more staining 
than the I+ St + DSP-4 group (especially in ROI 1, frontal cortex). In addition, it was 
found that Dj3H staining in DSP-4 and saline treated groups was significantly decreased 
in ROI 4 (hippocampus) compared to the other regions (p < 0.05). 
To investigate the possibility that NE projections were regenerating during the 
course of the study and whether housing had an effect on this, a subgroup of animals 
were sacrificed 1 week after DSP-4 injection. Comparison of Dj3H staining 1 and 9 
weeks post-treatment revealed that there was no significant effect of time but there was a 
trend in both groups for more staining at 9 weeks (Figure 3.7B). 
Regression analysis revealed that among ischemic animals in the ER groups there 
was a non-significant trend for decreased Dj3H staining to correlate with a higher 
staircase score at 9 weeks (data not shown). Among ischemic standard housed animals 
the correlation of decreased Dj3H staining and increased performance was significant for 
each ROI except ROI 2 (R = 0.50, 0.43 and 0.44 and p = 0.007, 0.02 and 0.02 for ROI 1, 
3 and 4 respectively). 
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3.3.4BDNF 
No significant differences in the amount of BDNF protein were found between 
the 4 ischemic groups in either hippocampi or the cortex contralateral to the lesion. 
There was however an effect of region (Fc4,26) = 384.786, p < 0.0001) due to the cortex 
containing significantly less BNDF than both hippocampi (p < 0.0001). There was a 
trend for the animals exposed to environmental enrichment to have higher levels of 
BDNF, and when DSP-4 and saline treated animals were pooled for housing conditions 
there was a significant effect of group (F(l,28) = 4.952, p = 0.0343). ER resulted in 
significantly higher levels ofBDNF in the contralateral hippocampus (CH), the 
contralateral hippocampus + the contralateral cortex (CH + CC) as well as for total 
BNDF in all three regions measured (p < 0.05 for all) (Figure 3.8). Pooling animals for 
drug treatment showed that DSP-4 had no effect on BDNF levels in the regions measured 
(data not shown). 
3.5 Discussion 
The goal of the present study was to determine ifNE is required for recovery of 
function after focal ischemia in rats. Accordingly, we depleted NE by injecting DSP-4 
one week after MCAo and we found no difference in infarct volumes between the groups 
that received DSP-4 and those that received saline. DSP-4 was given after MCAo since 
DSP-4 given prior to ischemia can affect injury outcome (Blomqvist et al., 1985; Nishino 
et al., 1991; Nellgard et al., 1999a). 
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We have shown here that ER facilitates recovery of function as previously found 
(Biemaskie and Corbett, 2001; Biemaskie et al., 2004) but in addition we have shown 
that depleting NE also facilitates recovery of function 9 weeks post-treatment regardless 
of housing. These results are at odds with those previously reported in short term (12 and 
19 days respectively) survival studies (Goldstein, 1991; Boyeson et al., 1992). In these 
studies the DSP-4 animals were more impaired than the respective controls at the start of 
behavioural testing, perhaps as a consequence of giving DSP-4 prior to the cortical injury 
(Goldstein, 1991; Boyeson et al., 1992). Further, infarct volumes were not measured in 
the Boyeson study (Boyeson et al., 1992) and no volumetric measures were provided in 
the Goldstein study (Goldstein, 1991). In the present study all groups were balanced for 
equal behavioural impairments prior to the initiation of treatments. Despite claims that 
depleting NE impeded recovery, the DSP-4 animals in the Boyeson study did fully 
recover if given an extra 5 days of training (Boyeson et al., 1992). Given that these DSP-
4 animals began the study with a more severe impairment, the rate of recovery appears to 
be approximately the same as their control animals. In the Goldstein study the DSP-4 
animals did not recover as much as the saline controls, but by the 12th day appeared 
similar to sham animals given DSP-4 (Goldstein, 1991). This suggests that recovery was 
not impeded by DSP-4 as previously suggested, but instead DSP-4 affected the baseline 
performance of the animals. In addition, these studies used only a beam walking test to 
evaluate functional outcome (Goldstein, 1991; Boyeson et al., 1992), and spontaneous 
recovery was seen after the somatosensory cortex lesion. 
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Clinical stroke can result in a large variety of motor deficits but commonly 
involves persistent upper extremity deficits (Parker et al., 1986; Nakayama et al., 1994). 
The present study used several tasks that have previously been shown to reveal different 
impairments in animal models of stroke, including forelimb reaching deficits, and show 
little spontaneous recovery (Montoya et al., 1991; Schallert et al., 1997; Biemaskie and 
Corbett, 2001; Metz and Whishaw, 2002). The most pronounced effects ofNE depletion 
were seen in the staircase reaching task. Animals housed in standard cages did not show 
recovery on the staircase test and it was only through intervention such as ER or NE 
depletion that some recovery occurred. 
The use of DSP-4 has been reported to be a reliable tool for depleting LC-NE 
terminals for as long as 8 months without permanent effects on DA, 5-HT or peripheral 
NE systems (Ross, 1976; Jonsson et al., 1981; Fritschy and Grzanna, 1991; Harro et al., 
2003). In the present study staining for D~H increased in both ischemic groups given 
DSP-4 over the course of the study but the increase was not significant and NE remained 
significantly depleted 9 weeks after DSP-4 administration. The present data show that 
LC-NE depletion facilitates forelimb function after ischemia since ischemic animals that 
received DSP-4 performed better in the staircase test than ischemic animals treated with 
saline in both housing conditions. There was a negative correlation between D~H 
terminal staining and staircase performance at the end of the study but this reached 
significance only in ischemic animals housed in standard conditions. This may be 
because animals housed in ER already improve to a greater extent than those in standard 
housing and although depletion ofNE augments the recovery it is not apparent in ER 
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animals due to a ceiling effect. The negative correlation supports the hypothesis that 
Dj3H fiber loss is the significant variable in improved recovery. 
The mechanisms by which depleting NE would facilitate recovery are unknown. 
Effects on other systems such as enhanced dopamine D2 receptor density and sensitivity, 
which might facilitate motor function (Harro et al., 2000; Harro et al., 2003) is one 
possibility. Alternatively, DSP-4 may enhance NE function in a way that would be 
beneficial to motor recovery. NE infusion into the cerebellum of animals with a 
unilateral lesion of the LC resulted in a heightened behavioural response (Boyeson et al., 
1993). This could have occurred because of selective increases in NE receptors, 
supersensitization of remaining receptors, sprouting of remaining NE terminals, or a 
combination of all three. Several studies have shown that DSP-4 treatment can up-
regulate and increase sensitivity of a 1- and 13-adrenergic receptors in the cortex and 
hippocampus which could facilitate the action ofNE released from remaining terminals 
(Dooley et al., 1983; Dunwiddie et al., 1983; Mogilnicka, 1986; Zahniser et al., 1986; 
Theron et al., 1993; Wolfman et al., 1994 ). It is unknown how long the receptor changes 
persist, but even transient changes may play a key role in shaping recovery. 
Important to the hypothesis that DSP-4 facilitates NE function is that the drug 
treatment did not totally eliminate Dj3H fiber staining. Regenerative sprouting of residual 
LC axons has been noted previously and even hyperinnervation of the frontal cortex has 
been observed 6 months after DSP-4 treatment (Fritschy and Grzanna, 1992). NE 
terminals were not completely removed in the present study and indeed there was a slight 
increase in Dj3H staining from 1 to 9 weeks post DSP-4 (see Figure 7B), which might be 
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important in the functional benefits seen. Since there are fibers remaining, an increase in 
NE turnover could compensate for decreased innervation. Microdialysis studies have 
shown that extracellular NE levels are unchanged (Kask et al., 1997; Nellgard et al., 
1999b) or even increased in areas of decreased tissue NE after DSP-4 treatment (Logue et 
al., 1985; Hughes and Stanford, 1998). Thus, physiologically effective NE release acting 
on supersensitive j3-adrenergic receptors might provide an enhancement ofNE function 
that would facilitate motor recovery as seen in the present study. Enhanced NE release is 
also consistent with reported down-regulation or decreased sensitivity of a.2-
adrenoreceptors following DSP-4 (Heal et al., 1993; Kask et al., 1997; Prieto and Giralt, 
2001). This hypothesis is speculative since the microdialysis studies were conducted 
within a week of DSP-4 treatment and it is unknown how long such levels are sustained. 
On the other hand, as mentioned earlier, even early events may shape later recovery. 
The greatest functional gains seen in the present study were in the ER + DSP-4 
group, which may be related to further facilitation ofNE function by ER. Environmental 
enrichment has previously been shown to increase NE in mice (Naka et al., 2002). In 
addition, repeated mild stress has also been shown to increase terminal sprouting in NE 
axons from the LC (Nakamura et al., 1989). Enriched rehabilitation could be viewed as a 
mild stress and in the present study ER animals did tend to have higher levels of Dj3H 
staining than standard housed animals, although the difference was not statistically 
significant. 
BDNF has been suggested to be crucial for experience-dependent plasticity as it 
can increase other mediators of plasticity such as synapsin I and growth associated 
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protein- 43 (Gomez-Pinilla et al., 2002). Rehabilitative therapies such as environmental 
enrichment (Falkenberg et al., 1992; Gobbo and O'Mara, 2004) and exercise (Russo-
Neustadt et al., 2000; Gomez-Pinilla et al., 2002; Vaynman et al., 2003; Ploughman et al., 
2005) increase BDNF levels. Similarily, NE has been suggested to be a modulator of 
BDNF given that several noradrenergic antidepressants increase BDNF in the brain 
(Nibuya et al., 1995; Russo-Neustadt et al., 2000) and that NE depletion attenuates 
exercise induced increases in BDNF (Garcia et al., 2003). In the present study we found 
that ER increased BDNF levels compared to standard housing, suggesting a possible role 
for BNDF in the improved functional recovery seen with ER. However, we found that 
depleting NE with DSP-4 did not alter BDNF levels. It is possible that NE function was 
maintained and therefore no change in BDNF would be expected, but it is also possible 
that changes in BDNF took place much earlier than when samples were taken (9 weeks 
post-DSP-4). Thus, it is possible that BDNF levels were transiently altered and then 
returned to normal, however this cannot be determined without further investigation. 
In conclusion, we have shown that depleting tissue NE using DSP-4 facilitates 
recovery of function after ET-1 induced MCAo. Whether this effect is mediated by 
decreased NE, effects on other neurotransmitter systems, or due to increased NE efflux 
and receptor supersensitivity remains to be determined, but it does highlight the need for 
further research on the role ofNE in recovery of function and neuroplasticity after focal 
ischemia. 
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Table 3.1. Infarct volume (mm3) 
Group Striatum Cortex Hemisphere 
I+ St 25.10 ± 2.84 68.71 ± 10.01 99.64 ± 16.40 
I+ St + DSP-4 17.40 ± 3.37 56.83 ± 7.41 78.42 ± 12.03 
I+ER 25.23 ± 2.59 43.94± 6.94 68.43 ± 9.95 
I+ ER + DSP-4 22.57 ± 1.83 40.81 ± 5.38 67.35 ± 6.82 
Values given are mean± SEM. 
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day7 1 week 
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Start of 
enrichment/ 
standard housing 
1 day later 
Figure 3.1. Time line of behavioural testing, drug administration and housing treatment. 
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Minimal Injury 
Typical Injury 
Maximal Injury 
Figure 3.2. Schematic illustration of the minimal, average and maximal amount of 
ischemic damage after ET-1 induced MCAo. 
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Figure 3.3. Performance in the staircase reaching task. All ischemic groups were 
impaired at pellet reaching with the contralateral limb compared to control animals. 
Enriched rehabilitation as well as depletion ofNE using DSP·4 resulted in enhanced 
recovery compared to animals housed in standard cages. Values given are mean ± SEM 
(* p < 0.001, ** p < 0.0001 compared to control group; t p< 0.01, tt p < 0.0001 
compared to I + St group). 
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Figure 3.4. Ipsilateral forepaw use in forelimb asymmetry test. All ischemic groups 
displayed increased reliance on the ipsilateral forepaw after ischemia but returned to 
normal levels within the first 2 or 6 weeks of post-ischemic testing. Values given are 
mean± SEM (* p < 0.001 compared to control group). 
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Figure 3.5. Mean number of errors/step in the ladder-rung walking task (A) as well as 
the decrease in errors/step from pre-treatment to 9 weeks post-treatment (B). All groups 
improved over time with the greatest improvement seen in the I+ ER and I + ER + DSP-4 
groups. Values given are mean± SEM (* p < 0.05, ** p < 0.0001 for difference in 
performance from pre-treatment to 9 weeks post-treatment). 
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Figure 3.6. D~H staining of motor cortex contralateral to the infarct in DSP-4 (A) and 
saline (B) treated animals (20 x magnification). Regions of interest (ROI) in which D~H 
staining was measured (C). Note that the shaded boxes represent the approximate area in 
which 3 measurements were taken. 
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Figure 3.7. Mean length (~-tm) ofD~H staining/10000 ~-tm2 9 weeks after DSP-4 
treatment (A) as well as a comparison of staining at 1 and 9 weeks (B). Four different 
regions of interest were examined for D~H staining, and in all regions the administration 
of DSP-4 resulted in a significant decrease in staining. In addition it was found that 
among saline treated animals there was significantly less staining in ROI 4 compared to 
the other regions examined. Values given are mean± SEM (* p < 0.01, ** p < 0.0001 
compared to respective saline treated group). 
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Figure 3.8. Effects of housing on BDNF protein levels in the ipsilateral hippocampus 
(IH), contralateral hippocampus (CH), contralateral cortex (CC) and the areas combined. 
Animals housed in ER showed increased BDNF levels in the contralateral hippocampus 
as well as the combined contralateral hippocampus and cortex (CH + CC) and all three 
regions combined (Total). Values given are mean± SEM (* p < 0.05). 
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Chapter 4: An Analysis of Four Different Methods of 
Producing Focal Cerebral Ischemia With Endothelin-1 in the 
Rat 
Published in Experimental Neurology October 2006 
4.1 Introduction 
There are a number of rodent focal ischemia models (Carmichael, 2005) but the 
most commonly used one involves occlusion of the middle cerebral artery (MCAo) 
(Kanemitsu et al., 2002) by insertion of an intraluminal suture (Ginsberg and Busto, 
1989; Longa et al., 1989). Focal ischemia can also be produced by coagulation of the 
MCA, by introducing an embolism or by photothrombosis (i.e. injection of rose-bengal). 
Middle cerebral artery occlusion produces a well-defined region of injury that includes 
the neocortex as well as the lateral striatum, resulting in sustained behavioural deficits 
(Ginsberg and Busto, 1989) that are of paramount clinical importance. Despite the 
widespread use of the above MCAo models, they have several drawbacks when used to 
study sensorimotor deficits: 1) the amount of injury is variable, particularly in transient 
focal models, 2) they often do not affect the motor cortex, 3) by blocking much of the 
length of the MCA by an intraluminal suture other arteries may also be occluded (Dittmar 
et al., 2003; McColl et al., 2004) leading to injury in brain regions not typically affected 
in human MCA stroke, and 4) surgeries are invasive and often result in feeding 
difficulties and deterioration of long-term health (Sharkey and Butcher, 1995; Dittmar et 
al., 200~). 
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Endothelin-1 (ET -1 ), a potent vasoconstrictor (Y anagisawa et al., 1988), reduces 
local blood flow to levels that produce ischemic injury when injected directly into brain 
tissue (Fuxe et al., 1997). Stereotaxic injection of ET -1 adjacent to the MCA is a less 
invasive procedure compared to methods that expose the artery or introduce a suture into 
the lumen, yet it produces a pattern of ischemic damage similar to the more traditional 
MCAo models (Sharkey et al., 1993). Stereotaxic injection ofET-1 can be delivered to 
conscious animals (Sharkey et al., 1993; Moyanova et al., 2003) and yields similar results 
to other focal ischemia models when investigating neuroprotective drugs (Sharkey et al., 
1994). It also produces long-term reaching deficits in the staircase task validating the 
model for studying recovery of function (Marston et al., 1995). In the ET -1 MCAo 
model blood flow reduction is rapid but not immediate (Macrae et al., 1993) and 
reperfusion occurs over several hours (Macrae et al., 1993; Biernaskie et al., 2001). This 
profile may be more representative of human stroke (not treated with t-P A) than the 
immediate reduction and reperfusion seen with the intraluminal suture or clip models of 
MCAo. Finally, it is possible to alter the amount of injury and improve consistency by 
increasing the concentration of ET -1 (Macrae et al., 1993 ). 
Nonetheless, due to variability in vessel location and size, accurate placement of 
ET -1 adjacent to the MCA is difficult, affecting the ischemic success rate and resulting 
sensorimotor deficits. Application of ET -1 to the surface of the cortex causes a dose-
related reduction of local blood flow for at least an hour, resulting in a well defined lesion 
(Fuxe et al., 1997). A variation of this model used by Adkins-Muir and Jones produced 
an injury that varied in size, yet was very consistent in location (Adkins-Muir and Jones, 
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2003). Intracortical injections ofET-1 into the forelimb region of the motor cortex 
produce lasting deficits in forepaw reaching ability with a recovery profile that is similar 
to that in other injury models (aspiration and quinolinic acid lesions) (Gilmour et al., 
2004). However, the optimal placement of ET -1 to produce sensorimotor deficits has not 
been explored. 
The purpose of this study was to evaluate different methods of delivering ET -1 to 
produce focal cerebral ischemia in order to create reliable sensorimotor deficits. Topical 
and intracortical applications were compared with injection adjacent to the MCA as well 
as to a combined approach of injecting ET -1 into both the cortex and striatum. Effects of 
the different models as well as effects of concentration of ET -1 were examined using 
three different sensorimotor tests and infarct measurements. In addition, magnetic 
resonance imaging (MRI) was performed on the cortical+ striatal injection model in 
order to compare outcome to previous data for MCAo induced by injection ofET-1 
adjacent to the MCA (Biemaskie et al., 2001). 
4.2 Materials and methods 
4. 2.1 Subjects 
A total of 115 male Long-Evans hooded rats (Charles River, Montreal, QC, 
Canada) weighing approximately 300 gat time of surgery were used in this study. All 
animals were socially housed in pairs in standard Plexiglas cages on a reverse day-night 
cycle (12 h) with the exception of those animals used in the MRI portion of the study. 
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Behavioural testing was performed during the dark phase. Food and water were provided 
ad libitum except during behavioural testing periods when food was restricted to 12-15 
g/day. All procedures were in accordance with guidelines set by the Canadian Council 
on Animal Care and approved by the Memorial University and University ofManitoba 
Animal Care Committees. 
4.2.2 Surgical procedures 
Animals were anesthetized initially with 2 % halothane in 30 % oxygen and 70 % 
nitrous oxide and were maintained with 1% halothane. Temperature was maintained 
between 36.5° C and 37.5° C throughout the surgery using a self-regulating heating 
blanket (Harvard Apparatus, Holliston, MA). Animals underwent one of the following 
surgeries that used ET-1 (human and porcine from Calbiochem, Cedarlane, Hornby, ON, 
Canada) in various concentrations dissolved in sterile saline. All stereotaxic 
measurements are relative to Bregma (Paxinos and Watson, 1986) and with depth 
determined from skull surface. 
4.2.2.1 Topical application 
Animals were placed in a stereotaxic apparatus, a midline incision was made and 
the bone and dura overlying the M 1 region of the cortex in the right hemisphere were 
removed (-1.75 mm to 3.25 mm anterior to Bregma, and 0.5 mm to 5.5 mm lateral) either 
by drilling several small burr holes or by using a 5 mm trepan. ET -1 was applied to the 
cortex using a Hamilton syringe in varying concentrations, to achieve a total of 1200 
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pmol (n = 9), 2000 pmol (n = 19), or 4000 pmol (n = 4) dissolved in 30, 20 and 10 ~I of 
saline, respectively. Groups were labelled topical 1200, topical2000 and topical4000, 
respectively. For the first two groups, application was followed immediately by placing 
sterile Gelfoam (Upjohn, Kalamazoo, MI), a gelatin sponge intended for slow release of 
the drug, over the exposed cortex and saturating it with additional drug (included in total 
pmol count). For the third group (topical4000) Gelfoam was not used. The hole was 
covered by Parafilm (secured with glue to prevent infection) and the incision sutured. 
4.2.2.2 Intracerebral injections 
Animals were placed in a stereotaxic apparatus, a midline incision was made and 
small burr holes were drilled at the coordinates given below. Using a 10 ~1 Hamilton 
Syringe, ET -1 was injected into the motor cortex (2 ~1) and in some animals into the 
dorsolateral striatum (2 ~1) as well, in either 400 pmol or 800 pmol amounts. The syringe 
was lowered and after 1 min ET-1 was injected at a rate of 1.0 ~1/2 min with a 1 min 
pause between each ~1 and a 3 min delay before syringe withdrawal. Five different 
protocols were used: 
1. cortical 800- 2 cortical injections of 400 pmol each (n = 4). Stereotaxic 
coordinates were anterioposterior (AP) 0.0 mm, +2.3 mm, mediolateral (ML) -2.5 
mm, dorsoventral (DV) -2.3 mm (for both injections). 
2. cortical 1600 - 2 cortical injection of 800 pmol each (n = 1 0). Same coordinates 
as above 
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3. cortical2400- 3 cortical injections of800 pmol each (n = 11). Stereotaxic 
coordinates were AP -1.0 mm, +1.0 mm, +3.0 mm, ML -2.5 mm, DV -2.3 mm. 
4. cortical+ striatal (c/s) 1200-2 cortical injections of 400pmol each+ 1 striatal 
injection of 400 pmol (n = 4). Stereotaxic coordinates were same as surgery #1 
for the cortical injections, plus AP +0.7 mm, ML -3.8 mm, DV -7.0 mm for the 
striatal injection. 
5. c/s 2400- 2 cortical of 800 pmol each+ 1 striatal injection of 800pmol (n = 13). 
Same coordinates as c/s 1200. 
4.2.2.3 MCA occlusion (MCAo) 
The protocol used for this model was as outlined in previous studies (Biemaskie 
and Corbett, 2001) except for an increased concentration of ET -1 and a minor 
adjustment to the DV coordinates. The accuracy of the coordinates was checked by 
injecting India ink and immediately removing the brain to confirm the proximity of the 
injection to the MCA (data not shown). Briefly a single injection of 600 pmol in 3 ~-tl was 
placed adjacent to the MCA at AP +0.9 mm, ML -5.2 mm, DV -8.2 mm (n = 8). 
4.2.2.4 Sham surgery 
In all of the above protocols sham surgeries involved replacing ET -1 with sterile 
saline (8 topical and 11 injected shams). 
4.2.3 Behavioral assessment 
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Three different behavioural tests were used to assess motor deficits out to one 
month post-ischemia. These tests encompass a range of difficulty and have demonstrated 
sensitivity in revealing long term functional deficits compared to simple neurological 
scores (Montoya et al., 1991; Schallert et al., 1997; Modo et al., 2000; Biemaskie and 
Corbett, 2001). 
4.2.3.1 Staircase reaching test (Montoya et al., 1991) 
This test consists of a chamber with a central platform for the rat to climb onto 
and a set of seven steps on each side. Each step holds three Noyes precision pellets (45 
mg, Research Diets Inc, New Brunswick, NJ). The rats remained in the staircase for 15 
min and the total number of pellets eaten on each side was recorded. This test provides a 
sensitive measure of skilled forelimb reaching ability, and also of sensory neglect. The 
animals were pre-trained twice per day over a 14-day period. Animals that failed to 
consistently retrieve over 55 % of the total available pellets were excluded from the 
study. Animals were retested for two trials per day on days 7 and 8 (1 week) after 
ischemia, as well as 30 and 31 days (1 montl)) post ischemia. Reaching ability was 
determined by averaging the score of the impaired limb over the 4 trials and calculating 
the percentage of pellets eaten compared to the average of the last 4 trials prior to stroke. 
4.2.3.2 Forelimb asymmetry test 
Animals were tested for limb preference and their ability to support weight on 
either forelimb by placing the animals in a 20 em diameter x 35 em high clear Plexiglas 
cylinder for 3 min (Schallert et al., 1997). As the animal rears to explore the environment 
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the number of bilateral paw placements, placements of the paw ipsilateral to the lesion 
(right), and placements of the paw contralateral to lesion (left) are counted. Normal 
animals use each limb more or less equally while ischemic animals favour their ipsilateral 
forelimb after injury (Schallert et al., 1997). The percent of ipsilateral limb use was 
calculated using the equation ipsilateral contacts/ (ipsilateral+ contralateral contacts) x 
100. Paw contacts were videotaped from below using an angled mirror and later 
analyzed in a blinded fashion. 
4.2.3.3 Balance beam test 
Animals were trained to cross a 2 em wide X 1.6 m long beam elevated 1 m above 
the floor. A black tube placed at the far end of the beam served as a goal box. Foot slips 
and falls were counted as faults. Animals were pre-trained for ten days and then given 4 
trials as a baseline. At 1 week and 1 month after ischemia the animals were given four 
trials and the number of foot faults per trial were averaged. Faults were recorded using a 
video camera and later analyzed in a blinded fashion. 
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4.2.4 Magnetic resonance imaging 
Ten animals underwent focal ischemia using the c/s 2400 method ofET-1 
application (see above). Six rats were examined using perfusion- and diffusion-weighted 
imaging at 1, 7 and 24 h (group A) and 4 animals were examined 3, 10 and 48 h (group 
B) after ET -1 administration. Group B rats were also examined with T 2-weighted 
imaging at 48 h. An additional 3 un-operated animals were imaged (2 were imaged 
twice) to obtain normal values for blood flow and diffusion parameters. MR imaging 
was performed using a Biospec/3 (Bruker, Karlsruhe, Germany) equipped with a 21 em 
bore magnet (7 Tesla, 3.2 em diameter and 4.5 em long). The rats were anesthetized with 
1.5 to 2 %halothane in a 70:30 mixture ofN20:02 and positioned in a quadrant 
radiofrequency coil (National Research Council, Winnipeg, MB, Canada). Rectal 
temperature was monitored and controlled using a water blanket and cooling air and 
respiration was monitored using electrocardiograph electrodes placed across the chest and 
a respiratory monitor (Hewlett-Packard, Palo Alto, CA). The imaging slice was 
positioned 1.2 mm anterior to bregma using as landmark the anterior commissure 
visualized on a sagittal scout image obtained at the midline. 
MR perfusion imaging was done with continuous arterial spin tagging (CAST) 
(Detre et al., 1992) as described previously (Lei and Peeling, 1999). Following spin 
labelling 5 mm posterior to the brain stem (2.5 s 15 mT block pulse with a 2 G/cm 
posterior-anterior magnetic field gradient) or control labeling symmetrically anterior to 
the imaging slice, perfusion-weighted snapshot fast low angle shot (FLASH) images ( 4 x 
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4 cm2 FOV, 2.0 mm thick slice, 128 x 128 matrix size, TR = 3.7 ms, TE = 2.3 ms, 12 
degree flip angle, 128 averages) were acquired using a four-step gradient-offset cycling 
protocol to eliminate the asymmetrical magnetization transfer effect. Cerebral blood flow 
(CBF) images were calculated (Detre et al., 1992) with the degree of spin tagging (a) and 
the blood-brain partition coefficient (A.) taken as 0.75 and 0.9 mllg, respectively (Lei and 
Peeling, 1999). 
Quantitative diffusion maps were obtained using magnetization prepared 
TurboFLASH (Thomas et al., 1998) (64 averages were accumulated in a 128 x 128 
matrix) with diffusion gradients (b = 21 1029 seconds/mm2) applied separately along the 
x, y and z axes. Apparent diffusion coefficient (ADC) values were calculated from the 
decay constant obtained by pixel-by-pixel intensity fitting to an exponential decay, and a 
directionally-invariant trace ADC map was calculated by averaging the ADCx, ADCy and 
ADCz maps (Ulug et al., 1997). 
4. 2. 5 Assessment of neuronal damage 
4.2.5.1 lfistolo~ 
Animals were sacrificed either at 48 h (MR study), 10 days or 1 month post-
ischemia to determine infarct volume at each time point. At the conclusion of each study, 
animals were injected with an overdose of Somnotol® and perfused transcardial1y with 
heparinized saline followed by 10 % phosphate buffered formalin. Heads were removed 
and placed in 1 0 % formalin for 24 h before removing the brain. The brain was stored in 
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10 % formalin for 24 h and then transferred to a 20 % sucrose solution in 10 % formalin 
and allowed to sink (approximately 3 days). Brains were frozen on dry ice and 40 ~-tm 
sections were cut using a cryostat (CM 3050 S, Leica, Germany). Every gth section was 
mounted and stained with Cresyl Violet. 
4. 2. 5. 2 Infarct measurement 
Sections stained with Cresyl Violet from +3.0 mm to -2.5 mm relative to Bregma 
were assessed for injury. Ischemic injury was determined by the absence of normal 
neuronal cell bodies and the border of the infarct was taken as the point at which marked 
gliosis ended. Every third slice was analyzed microscopically and the infarcted area in 
the cortex and striatum were separately traced using NIH image software. Volume of 
injury was calculated by summing the area recorded from each slice and multiplying that 
value by the distance between the measured slices (Buchan et al., 1992). 
4.2. 6 Statistics 
Behavioural and MR data were analyzed using repeated measures ANOV A or 
two-way ANOVA where appropriate. A Fisher's PLSD test was used to determine 
differences between groups, where p < 0.05 was considered significant. All values given 
are mean± SEM. 
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4.3 Results 
4.3.1 Infarct volumes 
The average infarct volumes for each surgical group for the cortex, striatum and 
the two measurements combined are given in Table 4.1. There was no difference 
between estimated infarct volumes at 1 0 days and 1 month and therefore the data were 
combined (data not shown). 
4.3.1.1 Cortical injury 
lntracortical injection of ET -1 in either the cortical or c/s models resulted in the 
largest cortical infarcts. Intracortical injection also resulted in larger variability of 
cortical injury than the topical and MCAo methods (see Table 4.1). There was no effect 
of concentration of ET -1 within each surgical method group although there was a trend 
for the higher concentration of cortical injections to result in a larger injury. Topical, 
cortical and c/s models resulted in similarly placed cortical lesions (see Figure 4.1), 
which were mainly confined to the forelimb motor region. Conversely the ET-1 MCAo 
model resulted in injury to the lateral cortex and most often spared the forelimb motor 
region (Figure 4.1 ). Three sham animals in the topical groups had slight injury to the 
cortex. These were animals that were operated on early in the study using a small drill bit 
for bone removal. Despite the small injury there were no detectable behavioural deficits 
in these animals. To avoid this non-selective injury in subsequent animals a trepan was 
used. 
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4. 3.1. 2 Striatal injury 
The topical method occasionally resulted in slight striatal injury just below the 
corpus callosum in animals with the largest cortical infarct. Striatal injury occurred more 
often using the cortical injection than the topical method, due likely to the larger injury. 
As expected, the combination of c/s resulted in a significant striatal injury that was 
statistically larger than in all other groups (p < 0.0001). There was no difference in injury 
produced with the two concentrations of ET -1 used for this method. The c/s and MCAo 
ET -1 models resulted in similar location of injury in the dorsolateral striatum (Figure 4.1) 
and only differed in the amount of rostral-caudal spread of the injury. None of the sham 
animals from any group had ischemic striatal injury. 
4.3.1.3 Total injury 
The concentration of ET -1 did not significantly alter the amount of injury. The 
average infarct in all topical groups was significantly smaller than those of the cortical 
1600 and 2400 groups as well as the c/s 1200 and 2400 groups (p < 0.05). In addition, 
the cortical 1600 and 2400 and the c/s 2400 groups had significantly larger infarcts than 
the MCAo group (p < 0.05). Among the animals subjected to the cortical and the c/s 
injection method there was no effect of surgery or concentration on the total amount of 
injury. Representative injury profiles for each ET -1 ischemic model are shown in Figure 
4.1. 
121 
4.3.2 Model success rate 
Table 4.2 summarizes the number of animals that survived the surgery and also 
the number of animals that exhibited significant reaching impairments, defined as any 
animal that had at least a 20 % reduction in performance in the staircase test at 1 we~k 
post-surgery. Animals with less than a 20 % deficit in the staircase task at 1 week were 
excluded from the behavioural portion of the study. While all four methods of applying 
ET-1 resulted in similar behavioural resl,llts (see below) the success· rates varied. 
Applying ET -1 adjacent to the MCA resulted in a success rate of only 50 %, much lower 
than any of the other methods (with the exception of the c/s 1200). In most cases 
increasing the concentration of ET -1 increased the percent of survivors with deficit and 
overall success. All animals exposed to the highest doses of ET -1 (top 4000, cor 2400 
and c/s 2400) that survived displayed behavioural deficits. 
4. 3. 3 Behavioural results 
Apart from success rate, the concentration of ET -1 did not appear to affect 
behavioural results (i.e. the severity of deficits did not differ between concentrations) 
therefore the animals from each concentration were pooled to represent each surgical 
method in the interest of reducing the number of animals in the study. 
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4.3.3.1 Staircase reaching test 
There was an effect of group 1 week (F(4,76) = 27.07, p < 0.0001) and 1 month 
(F(4,45) = 14.69, p = 0.0001) post-surgery. All groups were significantly impaired in the 
staircase reaching test compared to sham animals (p ::; 0. 0001) at both time points (see 
Figure 4.2). 
4.3.3.2 Forelimb asymmetry test 
There was an effect of group for the forelimb asymmetry task at 1 week (F(4,62) = 
16.94, p < 0.0001) with all surgical groups showing increased ipsilateral forelimb use 
compared to shams (p < 0.01, see Figure 4.3A). One month post-surgery (F(4,38) = 2.99, p 
= 0.03) all groups with the exception of the MCAo group remained impaired (p < 0.02) 
(see Figure 4.3B). 
4.3.3.3 Balance beam test 
There was an effect of group for balance beam at 1 week and 1 month (F(4,5S) = 
7.42, p < 0.0001, F(s,ss) = 8.59, p = 0.0002 respectively). While all groups had on average 
more foot faults than the sham group, only the cortical group was significantly different 
from the sham group at each time point (p < 0.0001 for both, data not shown). 
4. 3. 4 Magnetic resonance imaging 
ET-1 induced MCAo has previously been studied using MRI (Biemaskie et al., 
2001). Since the c/s model most closely resembled the MCAo model (both cortical and 
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striatal injury) and also had a high success rate we used MRI to further examine this 
model. Figure 4.4 shows perfusion and ADC images from two representative rats (1, 7 
and 24 h from one rat and 3, 10 and 48 h from another). CBF and ADC values were 
measured in 8 regions of interest (ROI) in both ipsilateral and contralateral hemispheres 
(see Figure 4.5 for diagrams showing location ofROI). ROI 1 encompasses the cingulate 
cortex and is just medial to the cortical injection of ET -1. ROI 2 is located approximately 
where ET-1 was injected into the motor cortex and is representative ofthe ischemic core. 
ROI 3, 4 and 5 represent increasingly lateral regions of the cortex. Since they had similar 
perfusion and diffusion values the data from these regions were pooled (ROI 345). ROI 
6, 7 and 8 were located in the lateral striatum and data from these regions were also 
pooled (ROI 678). 
4.3.4.1 Perfusion imaging 
Figure 4.5 gives the absolute CBF values for the above 4 regions in both 
hemispheres. For all regions normal values were taken from unoperated control animals 
and were assigned as time 0 post ET -1. In the ipsilateral hemisphere CBF was 
dramatically reduced in all ROI at 1 h (p ~ 0.0001). There was slight reperfusion 
beginning at 7 h for all regions except ROI 2 (the ischemic core), which didn't show any 
reperfusion unti148 h (Figure 4.5B). CBF in ROI 345 and 678 (Figure 4.5B and C) 
returned to normal levels by 48 h and ROI 1 was close to normal at 48 h (Figure 4.5A). In 
the contralateral hemisphere CBF was reduced in all regions compared to normal levels 
beginning at 1 h (p ~ 0.0001) but was most severely reduced in ROI 1 (Figure 4.5A). 
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With the exception of ROI 1, CBF in the ipsilateral hemisphere was significantly lower 
than CBF in the contralateral hemisphere (p < 0.05). 
4.3.4.2 Diffusion imaging 
In the ipsilateral hemisphere all regions showed a significant decrease in ADC 
values by 3 h (p < 0.05) that remained depressed out to 48 h (Figure 4.6) while in the 
contralateral hemisphere only ROI 1 showed a similar pattern. ADC values in all other 
contralateral regions were not significantly affected or only affected at a single time point 
(Figure 4.6B, C and D). 
4.3.4.3 T2 imaging 
T2-weighted MR images were used to determine the extent of injury caused by 
the c/s 2400 model at 48 h post ET -1. Infarct volumes estimated from T2-weighted 
images correlated with, but were significantly larger than the infarct volumes obtained 
from analyzing the same tissue stained with Cresyl Violet (r = 0.973 and 0.914 for the 
cortex and striatum, respectively; p < 0.05 for both regions). Volume estimates from T2 
images were 232.99 ± 55.36 mm3 in the cortex, 79.47 ± 17.29 mm3 in the striatum, and 
312.46 ± 72.69 mm3 combined. Infarct volumes measured from histological sections 
stained with Cresyl Violet were 134.37 ± 17.75 mm3 in the cortex, 33.34 ± 3.2 mm3 in 
the striatum, and 167.71 ± 20.31 mm3 combined for the rats examined with MR imaging. 
The cortical infarcts for this group were also significantly larger than the cortical volumes 
for the c/s 2400 group examined in the behaviour portion of this study (p ~ 0.0001). 
While only a portion of the motor cortex was injured in the previous c/s 2400 animals 
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(Figure 4.1) the animals used in MRI analysis had damage in this region and also in the 
lateral cortex (Figure 4. 7). Most animals also had injury to the contralateral cingulate 
cortex (ROI 1 ). In contrast, only one animal demonstrated contralateral injury on 
histological inspection of animals from the behavioural portion of the study. 
4.4 Discussion 
Occlusion of the MCA using the vasoconstrictor ET -1 is a common approach to 
produce focal ischemia in rodents (Sharkey and Butcher, 1995; Biemaskie et al., 2001; 
Callaway et al., 2003; Moyanova et al., 2003; Ploughman et al., 2005). The location of 
the MCAo injury in this study was similar to other results (Sharkey et al., 1993; Sharkey 
et al., 1994; Sharkey and Butcher, 1995) and size of the lesion was consistent with the 
lesion produced by Macrae and colleagues (Macrae et al., 1993). Despite a higher dose 
ofET-1, the average lesion size in this study was smaller than that obtained by Sharkey 
and colleagues (Sharkey et al., 1993; Sharkey et al., 1994; Sharkey and Butcher, 1995). 
This may be due, in part, to different rat strain and stereotaxic coordinates used in this 
study. Although proximity of the injection to the MCA was confirmed, a more distal 
portion of the MCA may have been occluded compared to other studies. Our findings 
also show that ET -1 MCAo produces long-term deficits in the staircase test at least 1 
month post-surgery as reported elsewhere (Marston et al., 1995). 
For the first time, we compared ET-1 induced MCAo directly with other ET-1 
induced focal ischemia models in order to directly compare sensorimotor deficits from 
model to model. All of the models tested in this study injured the forelimb motor cortex 
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and/or the dorsolateral striatum, and likely explains why all the methods resulted in 
similar motor deficits. The ET -1 induced MCAo model yielded a lower incidence of 
sensorimotor deficits compared to the other models. Previously we found that the MCAo 
method produces a success rate of only 50-60% (Biernaskie et al., 2001; Biernaskie et 
al., 2004), consistent with the current findings. 
Topical application ofET-1 provides precision in size and injury location as 
shown by the small variability in lesion size found in the present study. While increasing 
the dose of ET -1 did not have a significant effect on lesion size or behavioural outcome, 
others have found a dose-related increase (Fuxe et al., 1997). This may be due to a 
ceiling effect. The lesions produced in the present study were considerably larger than 
those reported by Fuxe and colleagues using a topical method (Fuxe et al., 1997). The 
doses for the present study were selected so as to create consistent and long lasting 
sensorimotor deficits while in the Fuxe study doses were used only to study reduced 
blood flow. While the topical model produced similar deficits to the ET -1 MCAo model, 
it had a higher success rate (75% versus 50%) suggesting it is more reproducible. One 
concern with this model is possible injury to underlying brain tissue caused by the 
craniotomy. Despite care when removing the bone, 3 out of 8 shams showed evidence of 
injury to the cortex, and while there was no obvious effect on behaviour, it suggests that 
some of the injury in this model is due to mechanical injury. One way to minimize injury 
due to craniotomy is to perform small intracortical injections. This method produced 
lesions in approximately the same location as the topical application, but they were larger 
and more variable in size (see Table 4.1). A smaller dose ofET-1 (e.g. 400 pmol) may 
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reduce variability in this model as suggested from findings of Gilmour and colleagues 
(Gilmour et al., 2004). Encouragingly, the smaller dose ofET-1 used in the Gilmour 
study still produced a reaching deficit that was apparent 12 weeks post surgery (Gilmour 
et al., 2004), but our results suggest that a lower dose ofET-1 produces a lower success 
rate (75% for cortical 800 versus 91 %for cortical2400). Despite these findings, all 
doses ofET-1 used for intracortical injections tested in this study yielded a higher success 
rate than the MCAo method of applying ET -1. 
The photothrombosis (i.e. rose-bengal) model of focal ischemia is similar to the 
cortical ET -1 model in that it does not require the removal of bone and can be precisely 
localized. However, it is a permanent ischemia model and its mechanisms of injury are 
complex (Carmichael, 2005). 
Clinical stroke often results in cortical and/or subcortical injury and consequently 
purely cortical injuries in the rodent may not be representative of the human stroke 
condition (Cramer, 2003). The combination ofintracortical and striatal injections 
produced a lesion that targeted the forelimb motor region of the cortex and dorsolateral 
striatum. Our results show that this method produces a significant and enduring deficit in 
reaching and forelimb asymmetry. At the highest dose (c/s 2400) this model produced a 
77% success rate, which is superior to that achieved with the MCAo model. 
Furthermore, all of the surviving animals demonstrated long-lasting impairments. We 
have previously found that combining cortical and striatal injections ofET-1 produces a 
high success rate (85 %) without excessive morbidity (Windle and Corbett, 2005), 
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especially when isoflurane was used instead ofhalothane. Use ofisoflurane does not 
increase the success rate of the ET-1 MCAo model (Biernaskie et al., 2004). 
We have previously described the spatial and temporal parameters ofCBF 
changes following low dose application ofET-1 adjacent to the MCA (Biernaskie et al., 
2001). Here we characterized the combined cortical and striatal model (c/s 2400) ofET-
1. We found that CBF drops quickly at 1 h, remains low for 48 h in the ischemic core 
(ROI 2) and gradually returns to normal in other regions. It is difficult to determine the 
flow rates and duration of CBF reduction 'required for permanent injury to occur. Indeed, 
the threshold of reduced CBF that marks metabolic failure increases with the duration of 
ischemia (Rossmann, 1994) which may vary between different models (Macrae et al., 
1993; Tsuchidate et al., 1997; Biernaskie et al., 2001). Injury to the contralateral 
cingulate cortex (ROI 1 ), although unexpected, provides an opportunity to examine CBF 
thresholds required to produce neuronal injury in this model. This region was the only 
contralateral region measured in which the CBF dropped below 50 ml/1 OOg/min. 
Although both injured (ipsilateral ROI 345) and uninjured (contralateral ROI 2) areas 
show similar reductions in CBF, they differ in the time to reperfusion. In spared regions 
(e.g. contralateral ROI 2), CBF increases above 100 ml/1 OOg/min by 7 h, while in injured 
regions (e.g. contralateral ROI 1 and ipsilateral ROI 345) CBF remains depressed below 
100 ml/1 OOg/min for 24 h. In summary, it appears that CBF must drop significantly (-
50 ml/1 OOg/min) and remain below 100 ml/1 OOg/min for at least 10 h in order for the 
tissue injury to occur in this model. Perfusion deficits below a certain threshold (which is 
variable depending on the duration of perfusion deficit) cause cells to undergo metabolic 
129 
energy failure, membrane depolarization and subsequent cell swelling that is observed as 
a reduction in ADC values (Back et al., 2004). In the current study, only those groups 
that meet the above criteria (CBF below 100 ml/1 OOg/min for at least 10 h) have ADC 
values that consistently remain below normal values. Decreases in ADC values and CBF 
below a certain threshold correlate with one another and together can predict areas of 
irreversible injury for the c/s 2400 model of ET -1 induced focal ischemia. 
We used T2-weighted MR imaging and histology to assess injury volume and 
found that they correlated, although lesions visualized by MR were larger. This was not 
unexpected as we noted the same effect previously using ET-1 induced MCAo 
(Biemaskie et al., 2001) and may be due to fixation changes. Importantly, the injury 
volume determined from the histological sections for the animals that underwent MRI 
was significantly larger than the estimated infarcts for the ischemic animals used in the 
behavioural portion of this study (not examined by MRI). In the rats that were imaged, 
damage extended into the contralateral cortex. The disparity between the infarct volumes 
measured for the MRI and behavioural portions of the study may be due, in part, to the 
shorter survival time (48 h versus 10 days or 1 month respectively). Although it is 
known that infarcted tissue may shrink over time resulting in an underestimate of injury 
volume (Back et al., 2004), it is unlikely to be the only reason for the large difference 
between the two groups in cortical infarct. The increased exposure to halothane (- an 
additional 6 h) may also have played a role in expanding the ischemic lesion. Increased 
exposure to halothane is used to create hypotension during global ischemia to increase 
injury size and reliability (Bendel et al., 2005) and has also been used to increase injury 
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in the suture model ofMCAo (Zhu and Auer, 1995). Prolonged and repeated exposure to 
halothane in the MRI portion of the study (- 7 h versus - 1 h in the behavioural portion) 
likely lowered blood pressure and resulted in the larger infarcts and may also explain why 
CBF was decreased in both hemispheres. In support of this interpretation, increasing 
halothane exposure from 5 to 180 min after ET -1 induced MCAo, increases cortical 
infarct volume from 17 %to 82 % (Sharkey and Butcher, 1995). This emphasizes the 
importance of consistent surgery length and anaesthetic exposure when using ET -1 to 
induce ischemia. 
As with all models of ischemia there are disadvantages with using ET -1. ET -1 is 
expressed by astrocytes in response to ischemia and previous studies have noted that ET-
1 has direct effects on neurons and astrocytes affecting excitability, gap junctions and 
gliosis (Hama et al., 1997; Dreier et al., 2002; Sanchez-Alvarez et al., 2004; Carmichael, 
2005). While ET -1 expression is normal after ischemia, using it to create ischemia could 
exacerbate the injury and should be considered when using ET -1 models, especially when 
studying neuroprotective agents. 
In summary, each ET-1 method ofinducing focal ischemia produced long-lasting 
impairments in forelimb reaching and postural support, although the MCAo group began 
to recover symmetry in postural support at 1 month. While all methods resulted in similar 
behavioural outcomes, they differed in success rate. ET -1 injected adjacent to the MCA, 
the most widely used of the methods tested, produced the lowest success rate. While 
occlusion of the MCA in the rat resembles human stroke in a number of respects it does 
not reliably produce upper limb deficits, a common clinical problem (Parker et al., 1986; 
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Nakayama et al., 1994). Cortical and striatal injections ofET-1 resulted in ischemic 
injury similar to MCAo but produced a more consistent injury and ensuing behavioural 
deficits resulting in a higher success rate. The increased reliability of the cortical+ 
striatal injection method, as well as the greater similarity to clinical stroke (compared to 
purely cortical models), makes it attractive for recovery studies. It is also useful for 
neuroprotective studies where it may not be possible to use behavioural testing or 
imaging to identify incomplete ischemia prior to drug treatment. 
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Table 4.1. Infarct Volume (mm3) 
Model Cortex 
topical 1200 
topical 2000 
topical 4000 
cortical 800 
cortical 1600 
cortical 2400 
c/s 1200 
c/s 2400 
MCAo 
20.20 ± 1.5 
17.88 ± 2.5 
19.80 ± 7.4 
63.60 ± 26.5 
86.07 ± 15.4*t 
80.29 ± 12.4*t 
36.20 ± 21.3 
60.48 ± 15.4* 
30.42 ± 6.8 
Striatum 
0.67 ± 0.67 
0.0 
0.45 ± 0.3 
0.0 
9.49 ± 5.0 
5.84 ± 4.4 
49.4 ± 7.7~ 
37.38 ± 4.8~ 
10.76 ± 2.6 
Total 
20.87 ± 1.6 
17.88 ± 2.5 
20.22 ± 7.4 
63.6 ± 26.5 
95.56 ± 18.8*t 
86.13 ± 16.1 *t 
85.6 ± 27.0* 
97.86 ± 18.7*t 
41.18 ± 9.1 
Values given are mean ± SEM, * significantly different from all topical groups (p < 
0.05), t significantly different from MCAo (p < 0.005 for the cortex and p < 0.05 for 
total),~ significantly different from all other surgical methods (p < 0.0001). 
c/s, cortical + striatal injection model; MCAo, middle cerebral artery occlusion model. 
Values in model name refer to the total pmol amount of endothelin-1 administered. 
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Table 4.2. Endothelin-1 Model Success Rate 
Model 
topical 1200 (n = 9) 
topical 2000 (n = 19) 
topical4000 (n = 4) 
pooled groups 
cortical 800 (n = 4) 
cortical 1600 (n = 11) 
cortical 2400 (n = 11) 
pooled groups 
c/s 1200 (n = 4) 
c/s 2400 (n = 13) 
pooled groups 
MCAo (n= 8) 
0/o survival 
100 
100 
100 
100 
100 
91 
91 
92 
75 
77 
76 
75 
% survivors with deficit 
89 
63 
100 
75 
75 
70 
100 
83 
67 
100 
92 
67 
o/o total success 
89 
63 
100 
75 
75 
64 
91 
77 
50 
77 
71 
50 
Percent survivors with deficit were animals that had at least a 20 % reduction in reaching 
performance in the staircase task at one week post- versus pre-surgery. 
c/s, cortical + striatal injection model; MCAo, middle cerebral artery occlusion model. 
Values in model name refer to the total pmol amount of endothelin-1 administered. 
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Topical Cortical Cortical + Striatal MCAo 
• Minimal Injury • Typical Injury Maximal Injury 
Figure 4.1. Representative illustrations of typical, minimal and maximal injury areas for 
each surgical method. The concentration of endothelin-1 (ET -1) did not significantly 
affect infarct volume. All animals were lesioned in the right hemisphere (left in each 
figure). 
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Figure 4.2. Staircase reaching test. All endothelin-1 models result in a significant deficit 
compared to sham animals at 1 week (A) and 1 month post-surgery (B). Values are mean 
± SEM (*p < 0.005, **p < 0.0001 difference from sham group). 
c/s, cortical + striatal model; MCAo, middle cerebral artery occlusion model. 
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Figure 4.3. Forelimb asymmetry test. All endothelin-1 groups exhibit a significant 
increase in ipsilateral forelimb use 1 week post stroke (A) that remains for all groups 
except MCAo at 1 month survival (B). Values given are mean± SEM (*p < 0.02, **p < 
0.0001 difference from sham group). 
c/s, cortical + striatal model; MCAo, middle cerebral artery occlusion model. 
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A 
1h 3h 7h 10h 24h 48h 
B 
Figure 4.4. Representative perfusion (A) and diffusion (B) images from 2 animals (1,7 
and 24 h post-endothelin-1 (ET-1) from one animal and 3, 10 and 48 h post-ET-1 from 
another). ET-1 was injected into the right hemisphere (appears on the right of each figure 
component). 
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Figure 4.5. Absolute cerebral blood flow (CBF) for select regions in the ipsilateral and 
contralateral cortex (A, Band C) and striatum (D). Blood flow in the ipsilateral 
hemisphere decreases quickly in all regions and gradually reperfuses over 48 h. Blood 
flow in the contralateral hemisphere decreased in all areas but was most severely reduced 
in region of interest (ROI) 1 (A), which was the only contralateral region to show 
histological injury. Values given are the mean± SEM. Values for 0 h post-endothelin-1 
(ET-1) are from animals that did not receive ET-1 and are considered normal(* p < 0.05, 
** p < 0.01 and*** p ~ 0.0001 relative to the normal value for the same hemisphere; t p 
< 0.05, tt p < 0.01 and ttt p ~ 0.0001 relative to the same time point in the contralateral 
hemisphere). 
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Figure 4.6. Apparent diffusion coefficient (ADC) values for select regions in the 
ipsilateral and contralateral cortex (A, Band C) and striatum (D). ADC values in all 
ipsilateral regions significantly differed from the normal values while only the value in 
contralateral region of interest (ROI) 1 differed from its normal value (A). Values given 
are the mean± SEM. Values for 0 h post-endothelin-1 (ET-1) are from animals that did 
not receive ET-1 and are considered normal(* p < 0.05, ** p < 0.01 and*** p:::; 0.0001 
relative to the normal value for the same hemisphere; t p < 0.05, tt p < 0.01 and ttt p:::; 
0.0001 relative to the same time point in the contralateral hemisphere). 
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Figure 4.7. Representative T2-weighted images showing the rostral-caudal extent of the 
injury (top-left to bottom-right) as a result of endothelin-1 (ET -1) injected into the cortex 
and striatum. The injury extends into the lateral cortex as well as the contralateral 
cingulate cortex as shown by increased signal (bright areas). ET -1 was injected into the 
right motor cortex and striatum (appears on the right of each figure component). 
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Chapter 5: Summary 
5.1 Summary of main findings 
5.1.1 Fluoxetine fails to improve functional recovery 
Previous work failed to show any benefit of fluoxetine treatment after ischemia 
(Jolk:konen et al., 2000). However, in this thesis (chapter 2) a more clinically relevant 
chronic dosing schedule combined with reaching rehabilitation was employed after focal 
ischemia. To date, animal and human studies have yielded contradictory results as to the 
efficacy of fluoxetine to enhance motor recovery after stroke. Therefore, a thorough re-
examination seemed warranted since positive clinical studies were not able to eliminate 
the effects of mood on rehabilitation and the previous negative rat study of fluoxetine 
(Jolk:konen et al., 2000) left doubt as to whether a more sensitive battery of tests, with 
prolonged and higher doses, or combining fluoxetine with therapy would be more 
effective. Despite the ability of fluoxetine to increase various forms of neural plasticity 
(e.g. increased brain derived neurotrophic factor (BDNF) and neurogenesis) (Nibuya et 
al., 1996; Coppell et al., 2003) no benefit on motor recovery was observed. It is possible 
that despite statistically significant changes in BDNF or other indices of plasticity as a 
result of fluoxetine administration, the changes are not sufficient to have an impact on 
motor recovery. The results of chapter 2 help reconcile previous discordant findings 
regarding fluoxetine's effects on motor recovery. 
147 
5.1.2 Norepinerine depletionfacilitates motor recovery 
The main finding of chapter 3 is that norepinephrine (NE) depletion facilitates 
recovery of function after ischemia. The previous findings of several earlier N-(2-
chloroethyl)-N-ethyl-2-bromobenzylamine (DSP-4) studies (Goldstein, 1991; Boyeson et 
al., 1992) have reported decreased NE to be detrimental to motor recovery after brain 
injury. However, these studies were flawed because NE was depleted prior to injury and 
this could have affected the development of the injury (i.e. the extent of cell death) and 
did affect the magnitude of post-injury behavioural deficits. Further, NE and other 
monoamines are decreased after brain injury (Robinson et al., 1975; Dunn-Meynell et al., 
1994; Prasad et al., 1994), therefore reducing NE after injury is more representative of 
the natural pathology process. The mechanism by which DSP-4 lesions facilitate motor 
recovery is unknown. It is possible that NE inhibits recovery as suggested by the 
negative correlation between Dj3H staining and staircase performance, but there are 
numerous data to support the hypothesis that increasing NE facilitates neural plasticity 
(Nibuya et al., 1995; Nibuya et al., 1996; Mal berg et al., 2000; Duman et al., 200 I), 
which would question this interpretation. The other possibility is that partially depleting 
NE projections establishes receptor supersensitization and increased NE turnover 
(Dooley et al., 1983; Dunwiddie et al., 1983; Logue et al., 1985; Mogilnicka, 1986; 
Zahniser et al., 1986; Theron et al., 1993; Wolfman et al., 1994; Kask et al., 1997; 
Hughes and Stanford, 1998) such that NE function is facilitated. Further investigation is 
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required to distinguish among these possibilities. Chapter 3 also found that depleting NE 
did not alter levels of BDNF. This could mean that the benefits ofNE on motor recovery 
are not mediated by BDNF as previously thought (Nibuya et al., 1996; Duman et al., 
2001), or that ifBDNF levels were altered, it was a transient change that occurred well 
before the time (9 weeks post-treatment) when BDNF levels were measured. 
5.1.3 ET-1 models offocal ischemia 
As a result of the experiments described in chapters 2 and 3 it became evident that 
different models of endothelin-1 (ET -1) induced ischemia were not equal with respect to 
reproducibility. This led to the experiment outlined in chapter 4 which compared 
different models of ET -1 induced focal ischemia with regard to producing consistent 
sensorimotor deficits. Each of the models was capable of producing similar sensorimotor 
deficits. However, the main finding of the study was that success rate (i.e. survival plus 
significant functional impairment) differed appreciably between models. Interestingly, 
the method that is most commonly used and the method used in chapter 3 (ET -1 applied 
to the middle cerebral artery (MCA) had the poorest success rate(- 50%). This finding 
was consistent with previous work from our laboratory (Biemaskie et al., 2001; 
Biemaskie et al., 2004). The combined injections ofET-1 into the motor cortex and the 
dorsolateral striatum, as used in chapter 2, resulted in a higher success rate (71 %in 
chapter 4 and 85 % in chapter 2) therefore establishing the greater reliability of this 
model. To further characterize this model, magnetic resonance imaging (MRI) data were 
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collected. Injection of ET -1 results in a prolonged decrease in cerebral blood flow (CBF) 
that differs depending on distance from the injection site. Blood flow is permanently 
decreased in the immediate region of the injection representing a permanent occlusion, 
however all other regions regain blood flow gradually (e.g. 7 to 48 h) representing a 
transient occlusion. In addition, the lesion evolves slowly over time which is consistent 
with human studies of stroke (Pantano et al., 1999). 
5.2 Implications for stroke patients 
The findings presented in this thesis may help to clarify issues regarding 
antidepressant use after stroke. Previous clinical studies in normal subjects and 
depressed stroke patients have suggested that serotonin specific reuptake inhibitors 
(SSRis) like fluoxetine might be beneficial to motor function and recovery after stroke 
(Dam et al., 1996; Loubinoux et al., 1999; Gainotti et al., 2001; Pariente et al., 2001 ). If 
this was the case then fluoxetine could be used in all stroke patients in order to facilitate 
recovery. No motor benefit was seen with fluoxetine in the present thesis and thus there 
is no basis for its use other than to treat depression. Also important is that fluoxetine did 
not impede recovery in these animals, suggesting that treatment in humans should not 
have a negative impact on their recovery. Indeed, fluoxetine may still facilitate motor 
recovery in humans indirectly by improving mood and as a consequence increasing the 
motivation of the patient's to participate in physiotherapy and daily activities. 
Noradrenergic antidepressants (i.e. tricyclics orNE reuptake inhibitors) are not 
commonly given to stroke patients because of the possibility of aggravating cardiac 
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complications (Robinson, 2003). Based on previous ideas about the role ofNE and 
recovery of function, NE antidepressants would seem advantageous for motor recovery 
and some investigators have recommended their use clinically (Gonzalez-Torrecillas et 
al., 1995). In addition, some studies have suggested that drugs that suppress NE, such as 
antihypertensives that are sometimes given after stroke, be avoided (Goldstein, 1991; 
Goldstein, 2000). The findings of the present thesis show that depleting NE projections 
from the LC is, in fact, beneficial although whether this is due to decreased NE or 
increased facilitation of the NE system remains to be determined. Obviously, the role of 
NE in stroke recovery is unclear and further research is warranted before 
recommendations can be made regarding the use or non-use of post-stroke drug 
treatments. 
5.3 Implications for research 
The findings of this thesis indicate that careful methodological procedures are of 
utmost importance when studying post-stroke recovery in animals. Previous studies have 
chosen a single behavioural test to show motor recovery after injury. Frequently such 
tests (e.g. beam walking) were ones in which animals show a high degree of spontaneous 
recovery, unlike most deficits observed clinically. Throughout this thesis multiple 
behavioural tests were chosen that were sensitive to both permanent and transient deficits 
as well as testing different aspects of sensorimotor function. For example, if only 
forelimb asymmetry had been used as an outcome measure in chapter 3 no effect ofNE 
depletion would have been observed, highlighting the importance for multiple and 
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varying tests. This may partly explain the different results found in the current thesis and 
previous DSP-4 studies that relied on a single beam walking task. Longer survival times 
were also used in this thesis, which is more reflective of the clinical situation. The 
importance of longer survival times was also reflected in chapter 3 since the benefits of 
depleting NE on motor recovery were not seen until later test points. 
As discussed in the introduction (chapter 1 ), the selection of an appropriate 
animal model is important for recovery of function and neuroprotection studies. There 
are several models of ET -1 induced focai ischemia, however the current literature does 
not provide useful information regarding the relative success rates of different models. A 
reliable animal model of stroke that can be used to investigate recovery processes is of 
obvious value. Accordingly, the findings of chapter 4 provide a better alternative model 
for researchers interested in using a transient ischemia model that avoids the many 
limitations of the currently widely used intraluminal suture model. 
5.4 Future directions 
The use nf antidepressants to facilitate rehabilitation after stroke remains 
controversial. The regulation of monoamines is extremely complex, and altering one 
neurotransmitter through drug therapy often indirectly alters others, making it difficult to 
make definitive conclusions (Gobert et al., 1998). Many of the early studies using 
pharmacological approaches to facilitate recovery examined amphetamine, which 
increases NE, serotonin (5-HT), and dopamine (DA). Recently it has been discovered 
that extracellular DA can be taken up by 5-HT transporters (Kannari et al., 2006) and 
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fluoxetine treatment can increase levels ofDA in the striatum (Shishkina et al., 2006). In 
addition, depletion ofNE has been shown to affect the metabolism ofDA and its D2 
receptor sensitivity (Harro et al., 2000; Harro et al., 2003) and increasing NE can also 
increase DA (Gobert et al., 1998). A small clinical study found that patients treated with 
levadopa prior to physiotherapy sessions improved more on motor tasks than those given 
a placebo (Scheidtmann et al., 2001). Given the well known role ofDA in motor 
function, it's contribution to recovery of function after stroke should be examined. 
While facilitating 5-HT may not be a sufficient approach, and more research is 
required to assess NE and recovery, there are other agents that may be beneficial by 
providing an environment conducive to neuronal growth and repair. Agents that increase 
plasticity, angiogenesis, tissue oxygenation and neurogenesis are·ofinterest. One agent 
of particular interest is Erythropoietin (EPO), a hematopoietic growth factor that is 
endogenous to the human brain. EPO has shown some promise in both animals and 
stroke patients as a neuroprotectant, likely due to its ability to promote neuron survival, 
neurogenesis, ischemic tolerance in astrocytes, decrease inflammation, and protect blood 
brain barrier integrity (for review see Hassel blatt et al., 2006). It may also play a 
significant role in rehabilitation. EPO and EPO receptor null mice have severely 
impaired embryonic neurogenesis and receptor knock down mice have decreased 
neurogenesis and neuroblast migration after distal MCA occlusion (Tsai et al., 2006). 
The role EPO plays in regulating neurogenesis suggests that it could be possible to 
promote recovery through neurogenesis by increasing EPO. EPO has also been found to 
be an important mediator of angiogenesis (Kertesz et al., 2004), which can be beneficial 
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in promoting neural plasticity. An attractive element ofEPO is that it is already approved 
for treatment in renal disease and has an excellent safety profile in humans (Goodnough 
et al., 1997), making it a good candidate to study as an adjunct to rehabilitation after 
stroke. 
Physiotherapy is an effective treatment for improving motor function and 
independence of stroke survivors, but there is room for improvement. Beginning therapy 
earlier and giving more frequent and intense treatment has been shown to improve 
functional outcome in both animal models of brain injury as well as stroke patients 
(Teasell and Kalra, 2005). The reality of this is that there are limited resources available 
for a growing population of stroke patients and as such the optimal time-to-therapy and 
therapy intensity may not be met. For this reason pharmacological enhancement of 
physiotherapy remains an attractive treatment option and deserves continued research. 
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